Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the mechanisms of tumor immune evasion, dynamic checkpoint regulation, and the evolution of mechanism-driven combinations and patient stratification.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
BBO-11818 is a potent, selective, orally bioavailable, and noncovalent pan-KRAS inhibitor targeting multiple clinically relevant KRAS mutants in both ON and OFF states.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-10182 | Laduviglusib |
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.
|
Breast Cancer
Pancreatic Cancer
Depression
Glucose Metabolism
Alzheimer's Disease
Obesity
Lung Fibrosis
|
321
|
| HY-100381 | Nigericin sodium salt |
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.
Source: Streptomyces hygroscopicus |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
258
|
| HY-127019 | Nigericin |
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
258
|
| HY-15147 | XAV-939 |
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Hypertension
Lung Fibrosis
|
209
|
| HY-13027 | DAPT |
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
|
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Digestive System Inflammation
Alzheimer's Disease
Rheumatoid Arthritis
|
172
|
| HY-50896 | Erlotinib |
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
|
|
147
|
| HY-L025 | Anti-Cancer Compound Library |
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,212 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
|
|
99
|
| HY-L004 | Cell Cycle/DNA Damage Compound Library |
DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.
MCE owns a unique collection of 3,495 cell cycle/DNA damage-related compounds which can be used in the research of the same.
|
|
93
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 820 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-L084 | Microbial Metabolite Library |
Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms, which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine.
MCE provides a unique collection of 934 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.
|
|
87
|
| HY-L017 | Stem Cell Signaling Compound Library |
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.
MCE owns a unique collection of 2,906 compounds that can be used for stem cell regulatory and signaling pathway research.
|
|
86
|
| HY-L020 | Wnt/Hedgehog/Notch Compound Library |
The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells.
The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development.
MCE designs a unique collection of 647 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.
|
|
86
|
| HY-L147 | Protease Inhibitor Library |
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. Proteases play important roles in regulating multiple biological processes in all living organisms, such as regulating the fate, localization, and activity of many proteins, modulating protein-protein interactions, creating new bioactive molecules, contributing to the processing of cellular information, and generating, transducing, and amplifying molecular signals.
Proteases are important targets in drug discovery. Some protease inhibitors are often used as anti-virus drugs and anti-cancer drugs. MCE offers a unique collection of 949 protease inhibitors. MCE Protease Inhibitor Library is critical for drug discovery and development.
|
|
86
|
| HY-L077 | Anti-Pancreatic Cancer Compound Library |
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.
MCE offers a unique collection of 4,305 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.
|
|
85
|
| HY-L053 | NMPA-Approved Drug Library |
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc.
MCE provides a unique collection of 1,536 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
|
|
84
|
| HY-L059 | Pyroptosis Compound Library |
Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.
MCE designs a unique collection of 2,008 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.
|
|
84
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,042 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L080 | Targeted Therapy Drug Library |
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.
There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.
MCE carefully collects a unique of 107 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.
|
|
84
|
| HY-L151 | PROTAC Library |
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.
MCE supplies a unique collection of 537 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.
|
|
84
|
| HY-L0086V | Specs HTS Compounds Library |
A unique collection contains 200,382 diverse chemical compounds to pharmaceutical and biotechnology scientists for drug discovery.
|
|
83
|
| HY-L0113V | 1M Drug Fragment-Based Diversity Library |
A diversity compound library contains 1,000,000 compounds with drug fragments. Each compound has at least one drug fragment. These selected molecules have 702,902 Bemis-Murcko Scaffolds (BMS) with drug-like chemical space. This library is highly recommended for AI-based lead discovery, ultra-large virtual screening and novel lead discovery.
|
|
83
|
| HY-L021M | Natural Product and Natural Product-Like Compound Library |
From the discovery of traditional Chinese medicine to modern antibiotics, natural products have played an important role in the drug development process. A review of all FDA-approved drugs shows that natural products and natural product-like compounds account for more than one-third of all approved drugs. Nearly half of that came from mammals, a quarter from microbes, and a quarter from plants. Over time, the proportion of microbial natural products and natural product derivatives in approved drugs has increased. Natural products have natural advantages in drug development and can be used as lead compounds in drug discovery for drug identification and mechanism research.
MCE provides a unique collection of 20,566 natural compounds and natural product-like compounds that contain saccharides and glycosides, phenylpropanoids, quinones, flavonoids, terpenoids and glycosides, steroids, alkaloid, phenols, acids and aldehydes. Natural product and natural product-like compounds library is a useful tool for drug discovery that can be used for high-throughput screening (HTS) and high-content screening (HCS).
|
|
83
|
| HY-L038 | Differentiation Inducing Compound Library |
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.
MCE Differentiation Inducing Compound Library contains a unique collection of 2,554 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.
|
|
83
|
| HY-L039 | Reprogramming Compound Library |
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.
MCE Reprogramming Compound Library contains a unique collection of 3,212 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.
|
|
83
|
| HY-L041 | Macrocyclic Compound Library |
Macrocycles, molecules containing 12-membered or larger rings, are receiving increased attention in small-molecule drug discovery. The reasons are several, including providing access to novel chemical space, challenging new protein targets, showing favorable ADME- and PK-properties. Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular processes such as protein–protein interactions (PPI). Otherwise, the size and complexity of macrocyclic compounds make possible to ensure numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity.
MCE offers a unique collection of 462 macrocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE Macrocyclic Compound Library is a useful tool for discovering new drugs, especially for “undruggable” targets and protein–protein interactions.
|
|
83
|
| HY-L074 | Anti-Breast Cancer Compound Library |
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,382 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
|
|
83
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,302 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L090 | Transcription Factor-Targeted Library |
Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.
MCE offers a unique collection of 2,537 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.
|
|
83
|
| HY-L100 | Tumorigenesis-Related Compound Library |
Cancer is a multi-step process which involves initiation, promotion and progression. Chemical carcinogens can alter any of these processes to induce their carcinogenic effects. People are continuously exposed exogenously to varying amounts of chemicals that have been shown to have carcinogenic or mutagenic properties in experimental systems. Exposure can occur exogenously when these agents are present in food, air or water, and also endogenously when they are products of metabolism or pathophysiologic states such as inflammation. The administration of chemical carcinogens is one of the most commonly used methods to induce tumors in several organs in laboratory animals in order to study oncologic diseases of humans.
MCE offers a unique collection of 147 chemical carcinogens which have been identified with carcinogenic activity either in humans or in animal models. MCE Tumorigenesis-Related Compound Library is a powerful tool for studying oncologic diseases of humans. Standard opration based on safety data sheet will not cause harm to the body.
|
|
83
|
| HY-L135 | Cancer Stem Cells Compound Library |
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.
Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.
MCE supplies a unique collection of 3,524 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.
|
|
83
|
| HY-L138 | Heterocyclic Compound Library |
Heterocyclic compounds are cyclic organic compounds which contain at least one hetero atom, the most common heteroatoms are nitrogen, oxygen ,and sulfur. Heterocycles are common in biology, featuring a wide range of structures from enzyme co-factors to amino acids and proteins. On the one hand, heterocycles are common structural units in approved drugs and in medicinal chemistry targets in the drug discovery process. In addition, heterocycles have been found as a key structure in medical chemistry and also they are frequently found in large percent of biomolecules such as vitamins, natural products ,and biologically active compounds including antifungal, anti-inflammatory, antibacterial, antioxidant, antiallergic, anti-HIV, antidiabetic, anticancer activity.
MCE offers a unique collection of 6,551 heterocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE heterocyclic compound library is critical for drug discovery and development.
|
|
83
|
| HY-L162 | Cell Death Library |
Cell death plays a crucial role in the development of the body and the maintenance of internal balance to prevent the development of diseases. According to the regulation of the involved processes, cell death can be defined as programmed and non-programmed death. Programmed cell death (PCD) can be divided into lytic cell death and nonlytic cell death, mainly including apoptosis, necrotic apoptosis and Pyroptosis. Non-Programmed cell death (Non-PCD) generally refers to necrosis. In stark contrast to Accidental Cell Death (ACD), Regulatory Cell Death (RCD) relies on specialized molecular mechanisms. Cell death includes internal apoptosis, external apoptosis, necrotic apoptosis, ferroptosis, pyroptosis, lysosome-dependent cell death, etc.
MCE designs a unique collection of 3,838 cell death compounds, covering multiple targets, such as Apoptosis, Ferroptosis, Pyroptosis, Necroptosis, etc. It is a useful tool for screening cell death drugs.
|
|
83
|
| HY-L162M | Cell Death Inhibitor Library Mini |
Cell death is a core biological process that maintains homeostasis in multicellular organisms, playing a dual role in life activities. On one hand, cell death participates in physiological processes such as cell renewal and damage repair through precise regulation; on the other hand, it actively eliminates damaged, infected, or cancerous cells, thereby blocking pathological progression and preserving organism health. Cell death not only ensures the normal development and growth regulation of organisms but is also closely associated with the occurrence and development of various diseases. Numerous studies have shown that specific types of programmed cell death play critical roles in disease progression, providing an important theoretical basis for developing novel therapeutic strategies by regulating cell death pathways.
MCE offers 23 types of commonly used cell death inhibitors, such as apoptosis, ferroptosis, pyroptosis, and cuproptosis, suitable for use as positive controls in the study of novel cell death mechanisms.
|
|
83
|
| HY-L174 | Macrophage Related Compound Library |
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.
MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L176 | Multi-Target Compound Library |
The occurrence of diseases is often associated with multiple targets and pathways, and the factors of disease formation are complex and diverse, so the development of more powerful drugs is needed. According to statistics, 21% of the FDA-approved drugs in 2015-2017 were multi-target compounds. Multi-target compounds refer to a drug targeting multiple disease-related targets or multiple subtypes of a target. Multi-target compounds can be applied to drug screening or targeted ligand design. Because the targets of such compounds are diverse and clear, they have the characteristics of saving time and drug cost during the mechanism research of new drug research and development. In addition, due to the diversity of drug targets, multiple strategies can be applied to pharmacological studies.
MCE supplies a unique collection of 7,296 multi-target compounds that targets two or more different targets or different subtypes of the same target. MCE Multi-Target Compound Library can be used for target protein ligand screening or drug development.
|
|
83
|
| HY-L177 | Antibody Inhibitor Library |
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.
MCE can provide 1,939 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.
|
|
83
|
| HY-L184 | Anti-Gastric Cancer Compound Library |
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.
MCE designs a unique collection of 1,193 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.
|
|
83
|
| HY-L201 | Cell Proliferation Compound Library |
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.
MCE collects 3,601 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.
|
|
83
|
| HY-L204 | Lactic Acid Metabolic Compound Library |
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism.
MCE contains 574 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L216 | Polysaccharides Compound Library |
Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development.
MCE offers 70 polysaccharides that can be used in biomedical studies.
|
|
83
|
| HY-L228 | Lipid Metabolite Compound Library |
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health.
One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses.
MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.
|
|
83
|
| HY-L236 | Amine Fragment Library |
Fragment-based drug discovery (FBDD) offers a strategic advantage by categorizing fragment hits according to their functional groups. This approach facilitates both the further optimization of these hits and the rational design of larger compounds through fragment combination. The amine functional group plays a vital role in drug development, as evidenced by its presence in many marketed drugs like Galantamine, Tacrine, and Rivastigmine. It is instrumental in enhancing solubility, improving bioavailability, and ensuring shelf-life stability—all critical factors for drug efficacy.
MCE offers a collection of 19,979 amine fragments for drug discovery. All of these compounds adhere to the Rule of Three (RO3) criteria for drug-likeness, which MCE offers a collection of 19,979 amine fragments for drug discovery, all of which stipulates a molecular weight ≤ 300 Da, ≤ 3 hydrogen bond donors, ≤ 3 hydrogen bond acceptors, and a cLogP ≤ 3.
|
|
83
|
| HY-L249 | Lactylation Compound Library |
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.
MCE has assembled a collection of 6,133 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.
|
|
83
|
| HY-L250 | Lactic Acid Metabolite Compound Library |
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies.
The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.
|
|
83
|
| HY-L917 | RNA Binding Library |
RNA is crucial for the regulation of numerous cellular processes and functions. With the in-depth study of disease mechanisms, processes such as RNA expression, splicing, translation, and stability regulation have become new targets for disease intervention. RNA has provided new therapeutic modalities for metabolic diseases, genetic disorders, and cancer patients, resulting in several innovative drugs.
MCE R&D team collected small molecules targeting RNA from the PDB, R-BIND, ROBIN, and internal database as the positive dataset, and non-targeting RNA small molecules from ROBIN as the negative dataset. Based on the GeminiMol pre-trained model, we encoded the molecules and calculated over 1700 molecular descriptors using Mordred as inputs for the model. Subsequently, we employed 13 deep learning models to learn from the data. All of which yielded good training results, with AUROCs greater than 0.75. Ultimately, we selected the Finetune model to screen HY-L901P, which exhibited the best classification performance, achieving an AUROC of 0.82 and a prediction accuracy of 0.76. We then applied filtering based on StaR rules (with at least two of the following properties: cLogP ≥ 1.5, Molar Refractivity ≥ 4, Relative Polar Surface Area ≤ 0.3) to obtain a library containing approximately 5,000 small molecule compounds targeting RNA. This library serves as a valuable tool for screening small molecules that interact with RNA.
|
|
83
|
| HY-L923 | Ion Channel Lead-like Compound Library |
Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.
MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.
|
|
83
|
| HY-L927 | 10K Golden Scaffold Library |
Designed to maximize efficiency in hit discovery and optimization, this compound library is built on a foundation of diverse Bemis-Murcko scaffolds, with each scaffold is represented by two specifically derived molecules. This strategy ensures broad chemical space through scaffold diversity while enabling preliminary functional group exploration. This approach provides early structure-activity relationship (SAR) insights for every scaffold, making it a valuable tool for accelerating drug discovery.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-10585A | Valproic acid sodium |
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
70
|
| HY-10585 | Valproic acid |
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
Infection
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Respiratory Disease
Small Cell Lung Cancer
|
70
|
| HY-14428 | ICG-001 |
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Digestive System Inflammation
Hypertension
Lung Fibrosis
|
68
|
| HY-101085 | SKL2001 |
SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.
|
|
67
|
| HY-120697 | MSAB |
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
60
|
|
| HY-16954 | ARV-825 |
ARV-825 is a BET protein PROTAC degrader that recruits cereblon, and it targets BRD2, BRD3, and BRD4 for degradation via the ubiquitin-proteasome pathway. ARV-825 downregulates c-MYC, PLK1, MYCN, CDK4/6, JAK2, pSTAT3/5, PIM1, and Bcl-xL, upregulates p21 and p27, and modulates H3K27Ac-mediated transcription, the G2/M checkpoint, the Wnt/β-catenin pathway, and amino acid transport pathways. ARV-825 induces G1 phase cell cycle arrest, caspase 3/PARP-mediated apoptosis, DNA damage, and reactive oxygen species (ROS) production, reduces mitochondrial respiration, and simultaneously inhibits cell proliferation, clonogenic growth, and cell migration. ARV-825 is used in research on gastric cancer, leukemia, neuroblastoma, and cholangiocarcinoma.
|
PROTACs
Epigenetic Reader Domain
c-Myc
Polo-like Kinase (PLK)
CDK
JAK
STAT
Pim
Bcl-2 Family
PAK
Wnt
β-catenin
Caspase
PARP
Apoptosis
Reactive Oxygen Species (ROS)
|
37
|
| HY-50752 | LY-411575 |
LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC50 of 0.39 nM.
|
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Neurodegenerative Disease
Digestive System Inflammation
Rheumatoid Arthritis
|
29
|
| HY-11102 | RO4929097 |
RO4929097 is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively.
|
Respiratory Disease
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Viral Infection
Neurodegenerative Disease
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Rheumatoid Arthritis
|
21
|
| HY-N0140 | Ursolic acid |
Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
|
|
21
|
| HY-W854659 | Chlorin e6 trisodium |
Chlorin e6 Ce6 (trisodium) is a water-soluble derivative of chlorophyll, belonging to the chlorin class of photosensitizers with an absorption wavelength range of 600-670 nm. Chlorin e6 trisodium emits characteristic red fluorescence upon light excitation, enabling real-time identification of tumor boundaries and progression. Chlorin e6 trisodium can be used for the study of photodynamic therapy (PDT) of cancers (bladder cancer) and fluorescence diagnosis of neoplastic lesions.
|
|
20
|
| HY-P1846A | Jagged-1 (188-204) TFA |
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
|
|
19
|
| HY-15096 | MKT-077 |
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity. MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm.
|
|
18
|
| HY-143218 | TPE-MI |
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .
|
|
18
|
| HY-N0133 | Tangeretin |
Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a Notch-1 inhibitor.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Digestive System Inflammation
Rheumatoid Arthritis
|
16
|
| HY-N0527 | Pentagalloylglucose |
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities.
|
Neurological, Eye or Ear Disease
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
16
|
| HY-N0711 | Carvacrol |
Carvacrol is an orally active and blood-brain barrier-permeable monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates Notch-1, and Jagged-1, and induces apoptosis. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Bacterial Infection
Fungal Infection
Digestive System Inflammation
Rheumatoid Arthritis
|
11
|
| HY-P1430A | 11R-VIVIT TFA |
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy.
|
|
9
|
| HY-P1430 | 11R-VIVIT |
11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy.
|
|
9
|
| HY-13526 | YO-01027 |
YO-01027 (Dibenzazepine;DBZ) is a potent γ-secretase inhibitor with IC50 values of 2.92 and 2.64 nM for Notch and APPL cleavage, respectively.
|
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Neurodegenerative Disease
Rheumatoid Arthritis
|
8
|
| HY-N0225 | (-)-Epigallocatechin |
(-)-Epigallocatechin (Epigallocatechin) is the most abundant flavonoid in green tea, can bind to unfolded native polypeptides and prevent conversion to amyloid fibrils.
|
|
6
|
| HY-113016 | Elaidic acid |
Elaidic acid is an orally active trans fatty acid. Elaidic acid enhances the stemness of colorectal cancer cells by activating the Wnt/ERK1/2 pathway, thereby promoting cell proliferation, invasion and metastasis, and inhibiting apoptosis. Elaidic acid also inhibits the growth of Lactobacillus and alters the cell surface hydrophobicity of Lactobacillus. Elaidic acid reduces basal 2-deoxyglucose uptake in muscle cells and adipocytes. Elaidic acid can be used in research on colorectal cancer, insulin and other related areas.
|
|
5
|
| HY-P2625 | GLP-2(3-33) |
GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM).
|
|
3
|
| HY-113293A | Estrone sulfate potassium |
Estrone sulfate potassium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate potassium is also a substrate of the OATP1B3 transporter. Estrone sulfate potassium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate potassium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate potassium is applicable to breast cancer-related research.
|
|
3
|
| HY-Y0344D | Sodium chloride, for cell culture |
Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells.
|
Small Cell Lung Cancer
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
|
3
|
| HY-113293B | Estrone sulfate sodium |
Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research.
|
|
3
|
| HY-164992 | Trastuzumab vedotin |
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
|
|
3
|
| HY-P99575 | Tarlatamab |
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.
Species: Human |
|
3
|
| HY-K0353 | Human CD3/CD28 T Cell Activation Magnetic Beads |
MCE Human CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation. |
|
3
|
| HY-P1682 | Balixafortide |
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.
|
|
2
|
| HY-N7043 | Isosilybin A |
Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity.
|
|
2
|
| HY-P1682A | Balixafortide TFA |
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.
|
|
2
|
| HY-P990859 | Anti-CD44 Antibody (Hermes-1) |
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a κ chimeric antibody, targeting to human CD44. Anti-CD44 Antibody (Hermes-1) blocks the binding of hyaluronan to CD44. Anti-CD44 Antibody (Hermes-1) restores (Platelet-derived Growth Factor-BB)-induced β-receptor activation and motility in fibroblasts. Anti-CD44 Antibody (Hermes-1) causes partial loss of the anti-aging effect of hyaluronic.
Species: Human |
|
2
|
| HY-N1511 | Ganoderic acid D |
Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells. Ganoderic acid D induces HeLa human cervical carcinoma apoptosis.
|
|
2
|
| HY-113011 | Maltotriose |
Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
|
|
2
|
| HY-N0175 | Cytisinicline |
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs, and partial to full agonist at β4 containing receptors and α7 receptors. Has been used medically to help with smoking cessation.
|
|
2
|
| HY-K0310 | Mouse CD8+ Cell Positive Selection Kit |
MCE Mouse CD8+ Cells Positive Selection Kit is designed for the isolation of CD8+ cells from single cell suspensions of mouse spleen cells, lymph nodes or other tissues. |
|
2
|
| HY-14261S | Vilazodone-d8 |
Vilazodone-d8 is the a deuterium labeled vilazodone, which is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist.
|
|
1
|
| HY-123298 | Chrysotoxine |
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.
|
|
1
|
| HY-N3198A | Sophoramine |
Sophoramine ((-)-Sophoramine) is a prejunctional α2-adrenoceptor inhibitor that can be found in the seeds of Sophora alopecuroides. Sophoramine inhibits prejunctional α2-adrenoceptors to facilitate norepinephrine release from adrenergic nerves. Sophoramine shows cytotoxic activity against human cancer cells, positive inotropic activity, and activity in rodent arrhythmia models. Sophoramine can be used for the research of arrhythmias.
|
|
1
|
| HY-N8505 | Lobelanine |
Lobelanine (8,10-Diphenyllobelidione) is a chemical precursor for the biosynthesis of Lobeline. Lobeline is a partial nicotinic agonist and is used as a smoking cessation agent.
|
|
1
|
| HY-163001 | Microcolin H |
Microcolin H is a marine lipopeptide and phosphatidylinositol transfer protein ligand that targets PITPα/β. Microcolin H increases the conversion of LC3I to LC3II and reduces p62 levels in cancer cells, leading to autophagy cell death (Autophagy). Microcolin H effectively inhibits tumor development and has anti-proliferative activity in nude mouse subcutaneous tumor models.
Source: Moorea producens |
|
1
|
| HY-114858 | Epiblastin A |
Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC50s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1.
|
|
1
|
| HY-N1453 | Hypocrellin B |
Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities.
Source: Hypocrella bambusae, Shiraia bambusicola |
|
1
|
| HY-N8572 | 3',4'-Dimethoxyflavone |
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Cardiovascular Disease
|
1
|
| HY-129139 | Cyanidin-3-O-arabinoside |
Cyanidin-3-O-arabinoside is a p38 MAPK phosphorylation inhibitor. Cyanidin-3-O-arabinoside reduces the expression of VDAC1, inhibits mtROS accumulation, reverses cellular senescence, blocks excessive mitochondrial calcium influx, reduces the formation of mitochondria-associated endoplasmic reticulum membranes, and suppresses the VDAC1-IP3R1 interaction. Cyanidin-3-O-arabinoside activates hair follicle stem cell proliferation and improves the condition of slowed hair growth. Cyanidin-3-O-arabinoside is applicable to research related to colon cancer and androgenetic alopecia.
|
|
1
|
| HY-Y1117 | Melamine |
Melamine is an orally active inducer of Apoptosis. Melamine induces animal disease models. Melamine affects the activity of Sertoli cell and can be used for research on male reproductive function. Melamine also has neurotoxicity and nephrotoxicity. Melamine induces cognitive impairment and acute kidney injury models. Melamine can also be used to induce bladder cancer and urinary stone models.
|
Environmental Pollutants
COX
ROS Kinase
Apoptosis
NF-κB
Drug Metabolite
NADPH Oxidase
TGF-β Receptor
|
1
|
| HY-W591424 | m-PEG2000-NHS ester |
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions.
|
|
1
|
| HY-18569B | 3-Indoleacetic acid,suitable for plant cell culture |
3-Indoleacetic acid, suitable for plant cell culture (IAA), is a naturally occurring plant growth hormone that is widely present in plants, bacteria, and fungi. 3-Indoleacetic acid, suitable for plant cell culture, is a plant growth-promoting hormone that not only promotes plant growth but also protects bacteria from the toxic damage to cell membrane potential caused by other indole intermediate products (such as I3P) produced during their own metabolic processes. 3-Indoleacetic acid, suitable for plant cell culture, can be used in plant cell culture.
|
|
1
|
| HY-121608 | Lumiflavin |
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer.
|
|
1
|
| HY-Y0537E | Potassium chloride, for cell culture |
Potassium chloride, for cell culture is potassium chloride that can be used for cell culture. Potassium chloride, for cell culture increases extracellular potassium ion concentration to induce cellular depolarization, thereby activating voltage-gated calcium channels and regulating intracellular calcium signaling. Potassium chloride, for cell culture upregulates Brn-5. Potassium chloride, for cell culture inhibits the proliferation of neurons and some plant cells.
|
|
1
|
| HY-Y1881B | Copper sulfate pentahydrate, for cell culture, 98% |
Copper sulfate pentahydrate, for cell culture, 98% is a biochemical reagent. Copper sulfate pentahydrate, for cell culture, 98% reduces the production of ROS and the expression levels of MyD88 as well as c-Rel genes. Copper sulfate pentahydrate, for cell culture, 98% decreases the activities of T-SOD, CAT, and GSH, increases the activities of caspase-3, caspase-8, and caspase-9. Copper sulfate pentahydrate, for cell culture, 98% is cytotoxic to various cells.
|
|
1
|
| HY-170230 | Bovine Endothelial cell growth supplement,suitable for cell culture |
Bovine Endothelial cell growth supplement, suitable for cell culture (ECGS, Bovine) is a culture medium supplement, endothelial cell growth supplement (ECGS), which promotes the proliferation of human saphenous vein endothelial cells (HSVEC) and human umbilical vein endothelial cells (HUVEC).
|
|
1
|
| HY-DY3003 | Tissue and Cell Fixative (4% Paraformaldehyde, PFA) |
Tissue and Cell Fixative (4% Paraformaldehyde, PFA) is mainly composed of paraformaldehyde, phosphate, and deionized water, with a pH of 7.0-7.4. Tissue and Cell Fixative (4% Paraformaldehyde, PFA) is suitable for fixing most tissues and cells, and can effectively protect the morphology and structure of tissues and cells as well as nucleic acids.
|
|
1
|
| HY-P7046 | IL-9 Protein, Human (CHO) |
|
1
|
|
| HY-K0306 | Mouse CD3+ T Cells Negative Selection Kit |
MCE Mouse CD3+ T Cells Negative Selection Kit is designed for the isolation of CD3+ T cells from single cell suspensions of mouse spleen cells and lymph nodes. |
|
1
|
| HY-K0307 | Mouse CD4+ T Cells Negative Selection Kit |
MCE Mouse CD4+ T Cells Negative Selection Kit is designed for the isolation of CD4+ T cells from single cell suspensions of mouse spleen cells and lymph nodes. |
|
1
|
| HY-15371G | Forskolin (GMP) |
Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin (GMP) is also an inducer of intracellular cAMP formation. Forskolin (GMP) induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy.
|
|
/
|
| HY-168968S | ZJY-54 |
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC50 values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity.
|
|
/
|
| HY-N0565AS | Doxycycline-d3 (hydrochloride) |
Doxycycline-d3 hydrochloride is deuterium labeled Doxycycline hydrochloride (HY-N0565A). Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
|
/
|
| HY-N0565S3 | Doxycycline-13C,d3 |
Doxycycline-13C,d3 is 13C and deuterium labeled Doxycycline (HY-N0565). Doxycycline is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
|
/
|
| HY-179219S | RTx-303 |
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC50 = 5.1 nM). RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer.
|
|
/
|
| HY-W010062R | 4-Chlorophenylacetic acid (Standard) |
4-Chlorophenylacetic acid (Standard) is the analytical standard of 4-Chlorophenylacetic acid (HY-W010062). This product is intended for research and analytical applications. 4-Chlorophenylacetic acid is an aromatase antagonist. 4-Chlorophenylacetic acid inhibits estrogen-induced breast tumorigenesis by blocking estrogen conversion. 4-Chlorophenylacetic acid also serves as the sole carbon and energy source for Pseudomonas sp. CBS3; it is degraded via dechlorination and aromatic ring cleavage pathways, and induces the synthesis of protocatechuate 2,3-dioxygenase. 4-Chlorophenylacetic acid can be applied to studies related to estrogen-induced breast tumors and bacterial degradation pathways.
|
|
/
|
| HY-50751G | Linifanib (GMP) |
Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells.
|
|
/
|
| HY-13526G | YO-01027 (GMP) |
YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent γ-secretase inhibitor.
|
|
/
|
| HY-12186G | 3-Deazaneplanocin A hydrochloride (GMP) |
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor.
|
|
/
|
| HY-D3209 | NIR-ASM |
NIR-ASM is a near-infrared fluorescent probe that can cross cell membranes and be activated by NQO1. NIR-ASM can distinguish NQO1-expressing cancer cells from normal cells via fluorescence microscopy and flow cytometry. NIR-ASM generates near-infrared fluorescence with a high signal-to-noise ratio in tumor models with NQO1 activity, enabling the detection of endogenous NQO1 activity in vivo. NIR-ASM is applicable to the research of lung cancer and breast cancer.
|
|
/
|
| HY-16397AS | Phenformin-d5 hydrochloride |
Phenformin-d5 (Phenethylbiguanide-d5) hydrochloride is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
|
|
/
|
| HY-12292G | IM-12 (GMP) |
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca2+ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABLT315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia.
|
|
/
|
| HY-180746 | N-Hydroxytyrosine |
N-Hydroxytyrosine is an early intermediates in the conversion of tyrosine to p-hydroxymandelonitrile.
|
|
/
|
| HY-P3563 | [Lys4] Sarafotoxin S6c |
[Lys4] Sarafotoxin S6c, a sarafotoxin analogue, is a potent and partial agonist of endothelin receptor. [Lys4] Sarafotoxin S6c elicits contraction of pig coronary artery, with an EC50 of 1.5 nM.
|
|
/
|
| HY-158220D | Hyaluronic acid methacryloyl (MW 300000) |
Hyaluronic acid methacryloyl (MW 300000) (HAMA (MW 300000)), a natural extracellular matrix (ECM) with anti-inflammatory effects, promoting cell adhesion and proliferation. Hyaluronic acid methacryloyl (MW 300000) can be widely used in tissue engineering and regenerative medicine. Hyaluronic acid methacryloyl (MW 300000) can rapidly form a hydrogel after exposure to UV light.
|
|
/
|
| HY-137474 | Purpurin 18 methyl ester |
Purpurin 18 methyl ester, a chlorophyll-a derivative, is a photosensitizer that can be used in photodynamic therapy (PDT). Purpurin 18 methyl ester has photodynamic activity to induce cancer cell death.
Source: sponge Stelletta clavosa |
|
/
|
| HY-181000 | PROTAC PLK1 Degrader-3 |
PROTAC PLK1 Degrader-3 (Compound DD-1) is a PLK1 PROTAC degrader based on the N-deglycosylation pathway, with a Kd value of 2.2 μM. The cell penetration ability of PROTAC PLK1 Degrader-3 is limited and a higher concentration is required to achieve significant degradation effects. PROTAC PLK1 Degrader-3 can be used for research on non-small cell lung cancer.
|
|
/
|
| HY-P992163 | 23ME-01473 |
23ME-01473 is an anti-ULBP6/2/5 antibody with enhanced Fc effector function, with a Kd of 0.053 nmol/L against hULBP6, 0.23 nmol/L against hULBP2, and 1.92 nmol/L against hULBP5. 23ME-01473 restores anti-tumor immunity by activating NKG2D and FcγRIIIa. 23ME-01473 exerts anti-cancer activity in non-small cell lung cancer PDX models. 23ME-01473 can be used for the research of non-small cell lung cancer.
Species: Human |
|
/
|
| HY-141520G | ART558 (GMP) |
ART558 (GMP) is ART558 (HY-141520) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. ART558 is a potent, selective and allosteric DNA polymerase theta (Polθ) inhibitor (IC50=7.9 nM). ART558 elicits BRCA-gene synthetic lethality and DNA damage. ART558 can be used for the research of cancer, such as breast cancer.
|
|
/
|
| HY-N19121 | 1-Methoxydehydroherbarin |
1-Methoxydehydroherbarin is an artificial pyranonaphthoquinone heptaketide. 1-Methoxydehydroherbarin is formed via the conversion of 1-hydroxydehydroherbarin during methanol extraction of cultures of the endolichenic fungus Corynespora sp. BA-10763, and exhibits no significant inhibitory activity against cancer cell migration and proliferation.
Source: Corynespora sp. |
|
/
|
| HY-W700452 | Y-27632-d4 hydrochloride hydrate |
Y-27632-d4 hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.
|
|
/
|
| HY-B0520AS1 | Benztropine-d3 mesylate |
Benztropine-d3 (mesylate) is the deuterium labeled Benztropine mesylate. Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects.
|
|
/
|
| HY-N7043R | Isosilybin A (Standard) |
Isosilybin A (Standard) is the analytical standard of Isosilybin A (HY-N7043). Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity.
|
|
/
|
| HY-P992450 | REGN6569 |
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001.
Species: Human |
|
/
|
| HY-P992369 | HMBD-002 |
HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8+ T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models.
Species: Human |
|
/
|
| HY-15947G | Ravoxertinib (GMP) |
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
|
|
/
|
| HY-129694 | Lenoremycin |
Lenoremycin (Ro 21-6150) is a microbial metabolite. Lenoremycin decreases β-catenin and cyclin D1 proteins levels. Lenoremycin decreases cancer stem cells (CSCs) populations via inducing reactive oxygen species production.
Source: Streptomyces hygroscopicus |
|
/
|
| HY-P99881 | Rolinsatamab talirine |
Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors.
|
|
/
|
| HY-P991516 | TB-402 |
TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR).
Species: Human |
|
/
|
| HY-P5327 | r8 Bid BH3 |
r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)
|
|
/
|
| HY-D3182 | AldRed 588-A |
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
|
|
/
|
| HY-113293S1 | Estrone sulfate-d4 TEA |
Estrone sulfate-d4 TEA is the deuterium labeled Estrone sulfate TEA. Estrone sulfate is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate is also a substrate of the OATP1B3 transporter. Estrone sulfate can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate is applicable to breast cancer-related research.
|
|
/
|
| HY-N21980 | 5α-Epoxyalantolactone |
5α-Epoxyalantolactone is an orally active, blood-brain barrier-permeable ANXA2 inhibitor. 5α-Epoxyalantolactone binds to ANXA2, blocks the formation of ANXA2-S100A10 heterotetramers, inhibits the membrane trafficking of E-cadherin, and prevents metastasis of breast cancer cells as well as proliferation of breast cancer stem cells. 5α-Epoxyalantolactone improves cognitive and memory impairments by inhibiting the iNOS/COX-2/NF-κB pathway and reducing the activity of cerebral AChE. 5α-Epoxyalantolactone can be used in studies related to Alzheimer's disease and triple-negative breast cancer.
|
|
/
|
| HY-10019S1 | Varenicline-15N,13C,d2 |
Varenicline-15N,13C,d2 is 15N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
|
|
/
|
| HY-P992360 | GT-002 |
GT-002 is a partial positive allosteric modulator targeting the α3 subtype of GABAA receptors, as well as a specific binder of tumor-associated TF-glycosylated LYPD3. GT-002 mildly enhances GABA-induced chloride currents by binding to the benzodiazepine site of GABAA receptors, thereby alleviating prefrontal hypofunction and improving cognitive, memory and social interaction abilities. GT-002 can be used in research related to schizophrenia spectrum disorders, various squamous cell carcinomas, colorectal cancer, non-small cell lung cancer, and aromatic L-amino acid decarboxylase deficiency.
Species: Human |
|
/
|
| HY-P5517 | SNNF(N-Me)GA(N-Me)ILSS |
SNNF(N-Me)GA(N-Me)ILSS is a biological active peptide. (Double N-methylated derivatives of amyloidogenic and cytotoxic partial IAPP sequence)
|
|
/
|
| HY-B1826S2 | Adefovir-d4 |
Adefovir-d4 is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses.
|
|
/
|
| HY-P991854 | Anti-iNKT Cell Antibody (6B11) |
Anti-iNKT Cell Antibody (6B11) recognizes an epitope on T cell receptor (TCR) V alpha 24-J alpha 18. Anti-iNKT Cell Antibody is specific for cloned and primary human but not rodent iNKT and the human invariant TCR-α. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
Species: Human |
|
/
|
| HY-19337S1 | Ketodarolutamide-d6 |
Ketodarolutamide-d6 (BAY 1896953-d6) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells. Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs. Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer.
|
|
/
|
| HY-W127725 | Thymolphthalexon tetrasodium |
Thymolphthalexon (tetrasodium) is an organic compound commonly used as a reagent in biochemical assays. It belongs to the family of thioxanthone derivatives and has strong antioxidant properties. Thymolphthalexon has several applications in the study of free radical response, oxidative stress, and aging. In addition, it can be used as a photosensitizer in photodynamic therapy for the improvement of cancer and other diseases.
|
|
/
|
| HY-D3311 | M1219 |
M1219 is a GSH/ATP dual near-infrared activated fluorescent probe that enables independent real-time monitoring of dynamic changes in intracellular GSH and ATP without spectral crosstalk (GSH: Ex=640 nm, Em=740~800 nm; ATP: Ex=594 nm/610 nm, Em=650~700 nm). M1219 not only visualizes the metabolic regulatory mechanism of TNBC under single/dual-target inhibition of SLC7A11/GLUT1 and accurately evaluates its in vivo efficacy, but also achieves precise localization of the TNBC tumor invasion boundary. M1219 can be used for the research of triple-negative breast cancer.
|
|
/
|
| HY-15150G | Bemcentinib (GMP) |
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
|
|
/
|
| HY-D3185 | AlDeSense AM |
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
|
|
/
|
| HY-P11852 | NOTA-cRY9M |
NOTA-cRY9M is a reagent targeting FGFR1 with a Kd value of 58 nM, and exhibits subtype selectivity for FGFR2-4. When radiolabeled as [68Ga]Ga-NOTA-cRY9M, it functions as a stabilizer, imaging contrast enhancer, and tumor-targeting agent, and accumulates in FGFR1-positive non-small cell lung cancer xenograft models. NOTA-cRY9M can be used in studies related to non-small cell lung cancer.
|
|
/
|
| HY-135146G | GSK-3484862 (GMP) |
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma.
|
|
/
|
| HY-DY1024 | TPE-MI (solution) |
TPE-MI (Tetraphenylethene maleimide) (solution) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
Solvent and concentration: DMSO: 10 mM |
|
/
|
| HY-D3353 | PSMA-SulfoCy7 |
PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies.
|
|
/
|
| HY-107614G | 1-Oleoyl lysophosphatidic acid sodium (GMP) |
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer.
|
|
/
|
| HY-D2095 | Medical fluorophore 33 |
Medical fluorophore 33 is a novel quinoline-isoquinoline salt. Medical fluorophore 33 exhibits a strong fluorescent signal, good microsomal stability and high biocompatibility in vivo. Medical fluorophore 33 has antitumor activity in colorectal cancer mice.
|
|
/
|
| HY-P5516 | SNNF(N-Me)GA(N-Me)IL |
SNNF(N-Me)GA(N-Me)IL is a biological active peptide. (Double N-methylated derivatives of amyloidogenic and cytotoxic partial IAPP sequence)
|
|
/
|
| HY-P2158 | Hemoregulatory peptide 5b |
Hemoregulatory peptide 5b is an acidic pentapeptide and also a selective inhibitor of myeloid hematopoiesis. Hemoregulatory peptide 5b inhibits myeloid hematopoietic colony formation, as well as the proliferation of committed myeloid hematopoietic stem cells and differentiating myeloid cells. Hemoregulatory peptide 5b exerts anticancer effects against mouse breast cancer and rat glioma. Hemoregulatory peptide 5b exhibits dose-dependent complex hematopoietic regulatory effects in vivo. Hemoregulatory peptide 5b can be used in research related to breast cancer, glioma, and lymphoma.
|
|
/
|
| HY-180885S | KRAS G12D-IN-35 |
KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer.
|
|
/
|
| HY-N0488S2 | Vincristine-d6 sulfate |
Vincristine-d6 (sulfate) is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
|
|
/
|
| HY-P4144 | Onvitrelin ucalontide |
Onvitrelin ucalontide (Phor18-LHRH (338613); EP-100) is a luteinizing hormone-releasing hormone (LHRH) receptor ligand. Onvitrelin ucalontide binds to functional LHRH receptors on cancer cells and mediates targeted cytotoxicity. Onvitrelin ucalontide reduces tumor volume, weight and the number of viable tumor cells in xenograft models. Onvitrelin ucalontide can be used for the research of breast cancer, ovarian cancer and prostate cancer.
|
|
/
|
| HY-162415 | CSF1R-IN-22 |
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8+ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8+ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs.
|
|
/
|
| HY-170905S | MAT2A-IN-22 |
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects.
|
|
/
|
| HY-P991730 | Kiatomab |
|
/
|
|
| HY-P11756 | P-LPK |
P-LPK is a dodecapeptide that specifically targets SLC1A5, which is highly expressed on the membrane of colorectal cancer cells, with a Kd value of 1.19 μM. P-LPK has no intrinsic cell proliferation regulatory activity. Gallium-68-labeled P-LPK selectively accumulates at colorectal cancer tumor sites in xenograft mouse models. P-LPK can serve as a targeted carrier to deliver Camptothecin (HY-16560) to colorectal cancer cells, forming the conjugate P-LPK-CPT. P-LPK can be used in the research of colorectal cancer.
|
|
/
|
| HY-P10711 | ALA-A2 peptide |
ALA-A2 is an anticancer peptide discovered in alpha-lactalbumin that selectively kills cancer cells by inducing Autophagy. ALA-A2 has cell-penetrating capabilities, allowing it to effectively enter cells without relying on membranolytic effects. In A549 lung cancer cells, ALA-A2 demonstrates significant dose-dependent anticancer activity. ALA-A2 holds promise for research in cancer therapy and autophagy regulation.
|
|
/
|
| HY-P11029 | CES |
CES (CESPLLSEC) is a homing peptide targeting Synaptosomal associated protein 25 (SNAP25). CES specifically homes in intracranial U87MG and the WT-glioblastoma (GBM) model. CES can be used as a targeting peptide for drug delivery for cancers research.
|
|
/
|
| HY-P3776 | a-Bag Cell Peptide (1-8) |
a-Bag Cell Peptide (1-8) is a NH2-terminal fragment α-bag cell peptide. α-bag cell peptide can inhibit the left upper quadrant (LUQ) neurons and the depolarization of the bag cells.
|
|
/
|
| HY-114703S | Eslicarbazepine-d3 |
Eslicarbazepine-d3 (BIA 2-194-d3) is the deuterium labeled Eslicarbazepine (HY-114703). Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
|
|
/
|
| HY-P992353 | ES009 |
ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer.
Species: Human |
|
/
|
| HY-N15716 | Orientalinone |
Orientalinone ((-)-Orientalinone) is an alkaloid that can be isolated from Papaver orientale. Orientalinone is also an intermediate in the conversion of Orientaline to (+)-Isothebaine.
|
|
/
|
| HY-P11018 | (123B9)2-L2-PTX |
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers.
|
|
/
|
| HY-Y1176S | Isonipecotic acid-d9 |
Isonipecotic acid-d9 is the deuterium labeled Isonipecotic acid. Isonipecotic acid is a GABAA receptor partial agonist.
|
|
/
|
| HY-P4139 | activable cell-penetrating peptide (ACCP) |
activable cell-penetrating peptide (ACCP) consists of a polycationic CPP (typically arg9 or r9) connected via a cleavable linker to a matching polyanion (typically glu9 or e9), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells.
|
|
/
|
| HY-P10988 | LVTX-8 |
LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model.
|
|
/
|
| HY-P11262 | GUB021794 |
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes.
|
|
/
|
| HY-P3305 | NBD-LLLLpY |
NBD-LLLLpY is an enzymatically forming intranuclear peptide for selectively killing human induced pluripotent stem cells.
|
|
/
|
| HY-P3777 | β-Bag cell peptide |
β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents.
|
|
/
|
| HY-P992209 | Anti-CD318/CDCP1 Antibody (25A11) |
Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research.
Species: Human |
|
/
|
| HY-113293BS | Estrone sulfate-d5 sodium |
Estrone sulfate-d5 sodium is the deuterium labeled Estrone sulfate sodium (HY-113293B). Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research.
|
|
/
|
| HY-D3186 | HMRef-βGal |
HMRef-βGal is a fluorescent probe and a substrate responsive to β-galactosidase (β-galactosidase) (Ex/Em=498 nm/505-600 nm). After being cleaved by β-galactosidase, HMRef-βGal triggers significant fluorescence enhancement via intramolecular spirocyclic function regulation. HMRef-βGal generates bright fluorescence in cancer cells with elevated β-galactosidase activity, enabling visualization of tiny peritoneal metastases in mouse models. HMRef-βGal exhibits low in vitro cytotoxicity and low acute in vivo toxicity in mice. HMRef-βGal can be used for preclinical fluorescence-guided diagnosis and cytoreductive surgery of peritoneal metastases, including compatibility with real-time naked-eye detection and endoscopic imaging, as well as for studies related to peritoneal metastases of ovarian cancer.
|
|
/
|
| HY-P10156 | MAP17 |
MAP17 (Cell-penetrating peptide MAP17) is a synthetic secondary amphipathic cell-penetrating peptides, with sequence of QLALQLALQALQAALQLA.
|
|
/
|
| HY-152852S | Mefatinib-d6 free base |
Mefatinib-d6 free base (Mifanertinib-d6) is the 6-labeled Mefatinib free base (HY-152852). Mefatinib free base is an orally active EGFR and HER2 kinase inhibitor with IC50 values of 0.4 nM and 11.7 nM, respectively. Mefatinib free base inhibits tumor growth in mouse models of lung cancer xenografts that overexpress EGFR/HER2, carry EGFR mutations, or carry Erlotinib (HY-50896)-resistant EGFR double mutations. Mefatinib free base can be used for the research of advanced EGFR-mutant non-small cell lung cancer.
|
|
/
|
| HY-175318S | p53 Activator 15 |
p53 Activator 15 is an orally active p53 Y220C activator. p53 Activator 15 enhances the DNA binding of p53 Y220C (SC50 = 0.58 nM) and significantly inhibits NUGC-3 cell proliferation. p53 Activator 15 effectively inhibits tumor growth in NUGC-3 xenograft mouse and rat models. p53 Activator 15 can be used to study gastric cancer.
|
|
/
|
| HY-10321G | PD173074 (GMP) |
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer.
|
|
/
|
| HY-B0847S1 | Propiconazole-d3 nitrate |
Propiconazole-d3 (nitrate) is the deuterium labeled Propiconazole nitrate. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS).
|
|
/
|
| HY-W743727 | Cytisine-d4 |
Cytisine-d4 is the deuterium labeled Cytisinicline (HY-N0175). Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs, and partial to full agonist at β4 containing receptors and α7 receptors. Has been used medically to help with smoking cessation.
|
|
/
|
| HY-P1755 | p53 (17-26) |
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.
|
|
/
|
| HY-W035399S1 | D-Lysine-d4 dihydrochloride |
D-Lysine-d4 dihydrochloride is the d4-labeled D-Lysine (HY-Y1091). D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
|
|
/
|
| HY-106234 | ZP 120C |
ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia.
|
|
/
|
| HY-D0919 | NIR-Red Dead Cell-3 Dye |
NIR-Red Dead Cell-3 Dye is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely used in traditional fields such as textile dyeing, as well as in emerging fields such as functional textile processing, food pigments and dye-sensitized solar cells.
|
|
/
|
| HY-132343S | Zolmitriptan N-Oxide-d6 |
Zolmitriptan N-Oxide-d6 is a deuterium labeled Zolmitriptan N-Oxide. Zolmitriptan N-Oxide is the major metabolite of Zolmitriptan. Zolmitriptan is a 5-HT1B/1D receptor partial agonist.
|
|
/
|
| HY-P11129 | MAGE-A4 (286-294) |
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
|
|
/
|
| HY-P1433 | [Pro3]-GIP (Rat) |
[Pro3]-GIP (Rat) is a selective GIP receptor partial agonist with a Ki of 13 nM. [Pro3]-GIP (Rat) can be used in diabetes research.
|
|
/
|
| HY-15772GL | Osimertinib (GMP Like) |
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer.
|
|
/
|
| HY-P3775 | a-Bag Cell Peptide (1-7) |
a-Bag Cell Peptide (1-7) is a NH2-terminal fragment α-bag cell peptide. α-bag cell peptide can inhibit the left upper quadrant (LUQ) neurons and the depolarization of the bag cells.
α-Bag Cell Peptide Fragment
|
|
/
|
| HY-P991211 | Bemiltenase alfa |
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia.
|
|
/
|
| HY-N16394 | 4-Hydroxyscytalone |
4-Hydroxyscytalone (Compound 3) is a microbial secondary metabolite. 4-Hydroxyscytalone can be isolated from the oak fungus Diplodia corticola. 4-Hydroxyscytalone has toxicity against Artemia salina with a LC50 of 90.6 μ/mL, but no significant antifungal activity. 4-Hydroxyscytalone can be used for cancer therapy research.
Source: Xylaria polymorpha |
|
/
|
| HY-15772G | Osimertinib (GMP) |
Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib (HY-15772). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer.
|
|
/
|
| HY-155031 | MCI |
MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC50 value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA).
|
|
/
|
| HY-P991744 | Anti-Mouse CXCR4 Antibody (Cx4Mab-1) |
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
|
|
/
|
| HY-16561G | Resveratrol (GMP) |
Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
|
|
/
|
| HY-P992388 | IO-108 |
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors.
Species: Human |
|
/
|
| HY-15150S | Bemcentinib-d8 |
Bemcentinib-d8 (R428-d8) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
|
|
/
|
| HY-P992339 | cT84.66 |
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies.
Species: Human |
|
/
|
| HY-P992473 | TAS266 |
TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors.
Species: Human |
|
/
|
| HY-14397G | Indomethacin (GMP) |
Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research.
|
|
/
|
| HY-W127809 | Chlorin e4 |
Chlorin e4 is an organic compound belonging to the family of chlorins, which are macrocyclic compounds with a similar structure to porphyrins. It is commonly used to improve photodynamic therapy for cancer and other diseases. Chlorin e4 has multiple applications in medical research, including as a photosensitizer for localized tumor destruction. In addition, its antimicrobial properties and potential use in disinfection applications were investigated.
|
|
/
|
| HY-P10513 | AcrAP1 |
AcrAP1 (AP1-Z1) is an antimicrobial peptide found in the venom of the Arabian scorpion (Androctonus crassicauda). AcrAP1 has antimicrobial activity and can inhibit the growth of Gram-positive and Gram-negative bacteria as well as yeast. AcrAP1 exerts antitumor activity by promoting apoptosis of cancer cells and inhibiting angiogenesis. AcrAP1 can be used in cancer therapy research.
|
|
/
|
| HY-P991585 | MORAb-028 |
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research.
Species: Human |
|
/
|
| HY-P5208 | CBLB 612 |
CBLB 612 is an anti-radiation agent. CBLB 612 can be used in the propagation of mouse and monkey moderate stimulation hematopoietic stem cell (HSC), and lure that they are passed to peripheral blood from bone marrow into. CBLB 612 is an important auxiliary agent for cancer.
|
|
/
|
| HY-P991634 | IBI-325 |
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
Species: Human |
|
/
|
| HY-W747797 | Cinobufagine-d3 |
Cinobufagine-d3 is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models.
|
|
/
|
| HY-121855 | 1-Monoelaidin |
Monoeladin is an ester derivative of glycerin and oleic acid, which are commonly found in various vegetable and animal fats. Monoeladin has unique chemical properties that make it an important intermediate in the biosynthesis of other lipid molecules, especially in the formation of triglycerides and phospholipids. It also plays a role in food science as a partial replacement for saturated fat, which has been linked to an increased risk of heart disease.
|
|
/
|
| HY-D3172 | BD-105 |
BD-105 (Glucagon Yellow) is a glucagon-binding fluorescent probe with a KD value of 13.3 μM. BD-105 exhibits changes in fluorescence intensity upon interaction with glucagon, and colocalizes with glucagon in cells and tissues. BD-105 is a selective cell stain that labels glucagon-secreting cells without staining insulin-secreting cells or non-endocrine control cells. BD-105 serves as an imaging reagent for glucagon in live cells and tissues (Ex/Em = 540 nm/580 nm).
|
|
/
|
| HY-12041G | SP600125 (GMP) |
SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis.
|
|
/
|
| HY-116705G | 2-Deoxy-2-fluoro-L-fucose (GMP) |
2-Deoxy-2-fluoro-L-fucose (2-Fluorofucose) GMP is a fucosyltransferase inhibitor that inhibits core fucosylation modification in cells. 2-Deoxy-2-fluoro-L-fucose GMP promotes the production of defucosylated IgG1 antibodies in IgG1-expressing cell culture systems; it regulates the levels of inflammatory cytokines such as IL-1β, IL-6 and TGF-β in human induced pluripotent stem cell-derived microglia. 2-Deoxy-2-fluoro-L-fucose GMP can be used in the research of related diseases including dengue fever and Alzheimer's disease.
|
|
/
|
| HY-P10220 | NOTA-COG1410 |
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium (68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
|
/
|
| HY-19337S | Ketodarolutamide-d3 |
Ketodarolutamide-d3 (BAY 1896953-d3) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells. Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs. Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer.
|
|
/
|
| HY-N18091 | Tovophyllin A |
Tovophyllin A is an orally active xanthonoid compound. Tovophyllin A exerts neuroprotective effects against Parkinson's disease by activating the Akt/GSK3β signaling pathway. Tovophyllin A protects mouse models of liver injury by activating Nrf2. Tovophyllin A exhibits protective anti-inflammatory activity in mouse models of acute lung injury. Tovophyllin A inhibits the activation of NF-κB and subsequent release of pro-inflammatory cytokines. Tovophyllin A reduces apoptotic cell death (Apoptosis). Tovophyllin A has antiplasmodial activity. Tovophyllin A shows cytotoxic activity against lung epithelial cancer cells and breast cancer cells. Tovophyllin A can be used in research related to Parkinson's disease, liver injury, acute lung injury, lung epithelial cancer, and breast cancer.
|
|
/
|
| HY-10019AS1 | Varenicline-d4 hydrochloride |
Varenicline-d4 hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A). Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively. Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment.
|
|
/
|
| HY-130569S2 | 7-Hydroxymethotrexate-d3 ammonium |
7-Hydroxymethotrexate-d3 (ammonium) is the deuterium labeled 7-Hydroxymethotrexate ammonium. 7-Hydroxymethotrexate is a major metabolite of Methotrexate (HY-14519). Methotrexate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.
|
|
/
|
| HY-20457G | TL8-506 (GMP) |
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
|
|
/
|
| HY-P99658A | Imaprelimab (powder) |
Imaprelimab (powder) is a humanized IgG1κ anti-CD146 antibody. Imaprelimab (powder) exerts anti-angiogenic effects on brain metastasis of lung cancer in animal models. Imaprelimab (powder) can be used in studies related to brain metastasis of non-small cell lung cancer.
Species: Human |
|
/
|
| HY-N144101 | SARS-CoV MPro-IN-2 |
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19.
|
|
/
|
| HY-P10325 | Kalata B7 |
Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V1a receptors.
|
|
/
|
| HY-N19738 | Obtusaquinone |
Obtusaquinone is a blood-brain barrier-permeable Keap1 inhibitor with anticancer activity. Obtusaquinone covalently binds to cysteine residues of Keap1, promotes its ubiquitination and proteasomal degradation, and activates the Nrf2 pathway. Obtusaquinone induces endoplasmic reticulum stress and DNA damage through abnormal accumulation of ROS, and triggers apoptosis of cancer cells. Obtusaquinone prolongs survival in orthotopic xenograft models of pediatric high-grade glioma, and exhibits antitumor activity in glioblastoma and breast cancer models. Obtusaquinone can be used in studies related to glioma and breast cancer.
|
|
/
|
| HY-W724404 | N-Oleoyl serinol-d5 |
N-Oleoyl serinol-d5 (Oleoyl serinol-d5) is the deuterium labeled N-Oleoyl serinol (HY-122788). N-Oleoyl serinol is a ceramide analog that can be used in stem cell therapy to prevent stem cells from developing into teratomas. N-Oleoyl serinol induces apoptosis in residual pluripotent embryoid body-derived cells (EBCs), prevents teratoma formation, and enriches EBC cells that undergo neural differentiation after transplantation.
|
|
/
|
| HY-P991566 | KD6001 |
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer.
Species: Human |
|
/
|
| HY-P11869 | PADI4_11 |
PADI4_11 is an isoform-selective, allosteric PADI4 activator with a Kd of 457 nM. PADI4_11 enters cells via active transport, does not induce cytotoxicity or membrane damage, and serves as a tool for investigating the regulation, function and cellular reprogramming of PADI4. PADI4_11 can be used in studies related to rheumatoid arthritis and ulcerative colitis.
|
|
/
|
| HY-P11492 | Hair cell targeting‐peptide A665 |
Hair cell targeting-peptide A665 is a hair cell targeting-peptide that specifically binds to the prestin protein on the surface of inner ear hair cells. Hair cell targeting-peptide A665 can be modified on the surface of nanocarriers and work in synergy with cell-penetrating peptides to enhance the permeability of the cylindrical window membrane, helping loaded drugs cross the blood-labyrinth barrier and enter the inner ear.
|
|
/
|
| HY-P992519 | PF-06940434 |
PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8+ T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4+CD25+ T cells on the cytotoxic activity of tumor CD8+ T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma.
|
|
/
|
| HY-Y1804S | D-Lysine-d4 monohydrochloride |
D-Lysine-d4 monohydrochloride is the d4 D-Lysine monohydrochloride (HY-Y1804). D-Lysine monohydrochloride is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine monohydrochloride is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine monohydrochloride blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine monohydrochloride specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine monohydrochloride can be used in research related to cancer and diabetes.
|
|
/
|
| HY-N0008R | Orcinol glucoside (Standard) |
Orcinol glucoside (Standard) is the analytical standard of Orcinol glucoside. This product is intended for research and analytical applications. Orcinol glucoside (OG) is an active constituent isolated from Curculigo orchioides, with antidepressant effects. Orcinol glucoside facilitates the shift of MSC fate to osteoblast and prevents adipogenesis via Wnt/β-catenin signaling pathway.
|
|
/
|
| HY-15244G | Alpelisib (GMP) |
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
|
|
/
|
| HY-D3240 | Photoactive NTR probe |
Photoactive NTR probe (Compound 1) is a covalent crosslinker and Fluorescent indicator targeting Nitroreductase. The Photoactive NTR probe undergoes a sequential activation process: it is first activated via nitroreductase-mediated nitro-to-amino conversion, and then forms a fluorescent product upon photoactivation. The Photoactive NTR probe can form covalent adducts with the side chains of cysteine, tyrosine, lysine and histidine in adjacent proteins to reduce fluorophore diffusion. The Photoactive NTR probe enables super-resolution (STORM) imaging of active mitochondrial nitroreductase microdomains in living cells.
|
|
/
|
| HY-N1511R | Ganoderic acid D (Standard) |
Ganoderic acid D (Standard) is the analytical standard of Ganoderic acid D. This product is intended for research and analytical applications. Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells. Ganoderic acid D induces HeLa human cervical carcinoma apoptosis.
|
|
/
|
| HY-W1123937C | Biotin-PEG5000-CHO |
Biotin-PEG-CHO (with a molecular weight of 5000) is a biotin-attached PEG derivative that can be used for biotinylation of biological molecules or other material surfaces. Biotin can be easily detected through the biotin/streptavidin binding test, and is widely used in molecular targeted detection.
|
|
/
|
| HY-N16371 | 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid |
6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid (Compound MC-1), an isocoumarin, is a metabolite of Cytogenin (HY-19606). 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid has anti-angiogenic activity in S-180 implanted dorsal air sac mice model. 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid also modifies collagen-induced arthritis. 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid can be used for cancers and inflammatory diseases research.
Source: Streptoverticillum eurocidium |
|
/
|
| HY-P11854 | SWQIGGN |
SWQIGGN is an oligopeptide targeting ovarian cancer cells. SWQIGGN inhibits the viability, proliferation, migration, invasion and cell adhesion of ovarian cancer cells and promotes apoptosis. SWQIGGN reduces ascites volume and tumor nodule formation in mouse models. SWQIGGN can be used in studies related to ovarian cancer.
|
|
/
|
| HY-D2620 | CAR-2 |
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models.
|
|
/
|
| HY-12299G | WH-4-023 (GMP) |
WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs.
|
|
/
|
| HY-N0565AG | Doxycycline (hydrochloride) (GMP) |
Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Prostate Cancer
Bladder Cancer
|
/
|
| HY-B0965S | Thioridazine 2-Sulfone-d3 |
Thioridazine-d3 2-Sulfone is the deuterium labeled Thioridazine hydrochloride. Thioridazine hydrochloride, an orally active antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine hydrochloride is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine hydrochloride shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs).
|
|
/
|
| HY-D2630 | Cy3 HA MA (MW 3000) |
Cy3 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-114703S1 | Eslicarbazepine-d4 |
Eslicarbazepine-d4 (BIA 2-194-d4) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
|
|
/
|
| HY-N15088 | Lunatoic acid B |
Lunatoic acid B has anti-mould (partial) and bacterial (individual) effects.
Source: Cochlioblus lunata |
|
/
|
| HY-113011R | Maltotriose (Standard) |
Maltotriose (Standard) is the analytical standard of Maltotriose (HY-13011). This product is intended for research and analytical applications. Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
|
|
/
|
| HY-N15349 | Nocapyrone Q |
Nocapyrone Q is a polyketide compound discovered in the karst cave mold Streptomyces sp. FD-2-6. At a dose of 100 μM, Nocapyrone Q exhibits inhibitory activity against human hepatocellular carcinoma HepG2 cells and human cervical cancer HeLa cells. Nocapyrone Q holds potential for research in the field of cancer therapy.
Source: Streptomyces sp. |
|
/
|
| HY-D2651 | Cy5 HA MA (MW 50000) |
Cy5 HA MA (MW 50000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 50000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-185679 | W19-LNP |
W19-LNP is a lipid nanoparticle formulated with a Ugi-reaction-derived ionizable lipid (W19). W19-LNP demonstrates highly selective mRNA delivery to the spleen in female BALB/c mice upon intravenous administration. W19-LNP can be used for the research of mRNA-based vaccine delivery, immune cell reprogramming, and gene-engineered cell preparation.
|
|
/
|
| HY-P990174 | Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) |
Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is an anti-mouse Pan-endothelial Cell Antigen/MECA-32 IgG2a monoclonal antibody. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) can label endothelial cells. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is often used for immunohistochemistry, delivery of siRNA and immunofluorescence.
Species: Mouse |
|
/
|
| HY-D2649 | Cy5 HA MA (MW 5000) |
Cy5 HA MA (MW 5000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 5000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-P990851 | Anti-c-Kit/CD117 Antibody (SR-1) |
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft.
Species: Human |
|
/
|
| HY-D2681 | Cy7 HA MA (MW 3000) |
Cy7 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY7 (HY-D0825). Cy7 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 740/770 nm).
|
|
/
|
| HY-P991957 | PRN100 |
PRN100 is a fully humanized anti-prion protein (PrPᶜ) monoclonal antibody belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 aims to prevent the recruitment and conversion of cellular prion protein into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the research of Creutzfeldt-Jakob disease.
|
|
/
|
| HY-158367 | 8(R)-HPETE |
8(R)-HPETE acts as an intermediate in the conversion of Arachidonic acid to pre-clavulone in Clavularia viridis.
Source: Plexaura homomalla |
|
/
|
| HY-N15346 | Menominin B |
Menominin B is a cyclic peptide found in the freshwater sponge-associated cyanobacterium Nostoc sp. with cytotoxic properties. Menominin B exhibits antiproliferative activity against the ovarian cancer cell line OVCAR3 (with IC50 of 2.4 μM). Menominin B holds promise for research in the field of anticancer therapy.
Source: Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607 |
|
/
|
| HY-130569S1 | 7-Hydroxymethotrexate-d3 |
7-Hydroxymethotrexate-d3 is the deuterium labeled 7-Hydroxymethotrexate. 7-Hydroxymethotrexate is a major metabolite of Methotrexate (HY-14519). Methotrexate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.
|
|
/
|
| HY-P991582 | BI-1607 |
BI-1607 is a humanized monoclonal antibody targeting FcγRIIB/CD32b. BI-1607 selectively blocks inhibitory FcγRIIB signaling, abrogates its inhibitory function, redirects tumor cell-bound antibodies to activating FcγRs, and its modified Fc region prevents the binding of its own Fc segment to FcγRs. BI-1607 reduces αPD-1 trogocytosis, enhances the effector functions of anti-tumor antibodies (including ADCP and ADCC, promotes intratumoral regulatory T cell (Treg) depletion, myeloid cell reprogramming, induction of interferon-γ (IFN-γ) and CXCL10, and increases the number of activated effector CD8+ T cells. BI-1607 can be used in research related to colorectal cancer, HER2-positive advanced solid tumors, HER2-positive locally advanced or metastatic breast cancer, and HER2-positive metastatic gastric cancer.
Species: Human |
|
/
|
| HY-D2632 | Cy3 HA MA (MW 10000) |
Cy3 HA MA (MW 10000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 10000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-D2633 | Cy3 HA MA (MW 50000) |
Cy3 HA MA (MW 50000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 50000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-B0847S | Propiconazole-d7 |
Propiconazole-d7 is the deuterium labeled Propiconazole. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 μM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 μg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS).
|
|
/
|
| HY-N8572R | 3',4'-Dimethoxyflavone (Standard) |
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Breast Cancer
|
/
|
| HY-W018324S | 5-Hydroxymethylcytosine-13C,d2 |
5-Hydroxymethylcytosine-13C,d2 is the 13C and deuterium labeled 5-Hydroxymethylcytosine (HY-W018324). 5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes).
|
|
/
|
| HY-D2650 | Cy5 HA MA (MW 10000) |
Cy5 HA MA (MW 10000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 10000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-D2634 | Cy3 HA MA (MW 100000) |
Cy3 HA MA (MW 100000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 100000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-10232S | THIP-d4 |
THIP-d4 (Gaboxadol-d4) is the deuterium labeled THIP (HY-10232). THIP (Gaboxadol) is a selective extrasynaptic GABAA receptors (eGABARs) agonist (with blood-brain barrier permeability), shows an EC50 value of 13 μM for δ-GABAAR. THIP induces strong tense GABAA-mediated currents in layer 2/3 neurons, but shows on effect on miniature IPSCs. THIP can be used in studies of sleep disorders.
|
|
/
|
| HY-D2648 | Cy5 HA MA (MW 3000) |
Cy5 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
|
|
/
|
| HY-D2215 | Mito-CCY |
Mito-CCY is a mitochondria-targeted, NIR-absorbing cryptocyanine probe. Mito-CCY displays a high photothermal conversion efficiency, good biological compatibility in vitro, and photoinduced cytotoxicity in HeLa cells.
|
|
/
|
| HY-D2631 | CY3 HA MA (MW 5000) |
Cy3 HA MA (MW 5000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 5000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
|
|
/
|
| HY-N15087 | Lunatoic acid A |
Lunatoic acid A has anti-mould (partial) and bacterial (individual) effects.
Source: Cochlioblus lunata |
|
/
|
| HY-N15180 | Corynantheidine |
Corynantheidine ((-)-Corynantheidine) is a mu-opioid receptor (MOR) partial agonist that shows MOR-dependent analgesic effects in mice.
|
|
/
|
| HY-122552 | Chrysotobibenzyl |
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394).
|
|
/
|
| HY-W248590 | IR-775 chloride |
IR-775 chloride is a cyanine dye with near-infrared absorption (Ex/Em = 775/795 nm). IR-775 chloride acts as a photosensitizer or photothermal agent, and induces apoptosis via generating ROS or exerting photothermal effects upon irradiation; its combination with 2-methoxyestradiol (HY-12033) inhibits SOD2 to enhance photodynamic therapy (PDT) efficacy, and its liposomal encapsulation enables phytotherapy-photothermal therapy (PTT) synergy. IR-775 chloride is applicable for investigating PDT/PTT and near-infrared fluorescence imaging in ovarian cancer and breast cancer.
|
|
/
|
| HY-P10553A | ARF(26-44), cell-permeable acetate |
ARF(26-44), cell-permeable acetate is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26-44) cell-permeable acetate shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26-44), cell-permeable acetate can be used in research on tumor therapy.
|
|
/
|
| HY-P11591 | PDI2 |
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
|
|
/
|
| HY-N11464 | Kuwanon O |
Kuwanon O is a flavonoid derivative with a fused dihydrochalcone partial moiety, that can be isolated from the root bark of Morus lhou (set.) Koidz.
|
|
/
|
| HY-P991689 | Girancitug |
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.
Species: Human |
|
/
|
| HY-P11280A | PRAME peptide (425-433) acetate |
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.
|
Breast Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
Lung Squamous Cell Carcinoma
Squamous Cell Carcinoma
|
/
|
| HY-P5358 | YFLLRNP |
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))
|
|
/
|
| HY-P10553 | ARF(26-44), cell-permeable |
ARF(26-44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26-44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26-44), cell-permeable can be used in research on tumor therapy.
|
|
/
|
| HY-P5931 | Spinoxin |
Spinoxin isolated from the venom of scorpion Heterometrus spinifer, is a 34-residue peptide neurotoxin cross-linked by four disulfide bridges. Spinoxin is a potent inhibitor of Kv1.3 potassium channel (IC50 = 63 nM), considering to be valid molecular targets in the diagnostics and therapy of various autoimmune disorders and cancers.
|
|
/
|
| HY-N9968 | Cucurbitacin C |
Cucurbitacin C is a tetracyclic triterpenoid compound. Cucurbitacin C exhibits significant in vivo and in vitro anticancer activity, which inhibits the PI3K/AKT signaling pathway to induce cell cycle arrest and apoptosis in cancer cells, and significantly suppresses the growth of HepG2 and PC-3 xenograft tumors in mice. Cucurbitacin C can be used in studies on plant defense mechanisms, secondary metabolism and cancer therapy.
|
|
/
|
| HY-W035399S | D-Lysine-d8 dihydrochloride |
D-Lysine-d8 dihydrochloride is the d8-labeled D-Lysine (HY-Y1091). D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
|
|
/
|
| HY-130569S | 7-Hydroxymethotrexate-d3 sodium |
7-Hydroxymethotrexate-d3 (sodium) is deuterium labeled 7-Hydroxymethotrexate. 7-Hydroxymethotrexate is a major metabolite of Methotrexate (HY-14519). Methotrexate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.
|
|
/
|
| HY-N0488S | Vincristine-d3 sulfate |
Vincristine-d3 sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
|
|
/
|
| HY-P99321 | Teneliximab |
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.
Species: Human |
|
/
|
| HY-B0965AS | Thioridazine-d3 hydrochloride |
Thioridazine-d3 (hydrochloride) is the deuterium labeled Thioridazine. Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs).
|
|
/
|
| HY-P990716 | Sabestomig |
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.
Species: Human |
|
/
|
| HY-P991217 | EU-103 |
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10−7 and 10−9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer.
Species: Human |
|
/
|
| HY-P2286 | D-3 |
D-3, a phosphorpeptide, is an efficient, simple, and specific iPSC-eliminating agent.
|
|
/
|
| HY-P5535 | Invopressin |
Invopressin (Compound 42) is a vasopressin V1A receptor partial agonist (EC50: 1.0 nM). Invopressin can be used for research of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
|
|
/
|
| HY-W110542H | Poly(ethylene glycol) diacrylate (MW 10000) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 10000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 10000) can be used to create a three-dimensional (3D) breast cancer cell culture model.
|
|
/
|
| HY-P4866 | Q-Peptide |
Q-Peptide is an angiopoietin-1 derived peptide (QHREDGS). Q-Peptide interacts with β1-integrin, binds to integrins on the surface of osteoblasts, and serves as an acyl donor substrate for Streptomyces mobaraensis transglutaminase. Q-Peptide activates Akt, MAPKp42/44, ILK, ERK1/2, and downregulates caspase-3/7. Q-Peptide inhibits cell apoptosis, enhances cell adhesion and migration, and promotes osteoblast differentiation, bone matrix deposition and mineralization. Q-Peptide can be used in studies related to myocardial infarction, bone regeneration, diabetic wound repair and human induced pluripotent stem cells.
|
|
/
|
| HY-137959 | Telmisartan acyl-β-D-glucuronide |
Telmisartan acyl-β-D-glucuronide is an acyl-β-D-glucuronide and a metabolite of Telmisartan (HY-13955). Telmisartan acyl-β-D-glucuronide can be converted back to Telmisartan upon incubation with Glucuronidase. Partial acyl migration of Telmisartan acyl-β-D-glucuronide occurs under physiological conditions.
|
|
/
|
| HY-126057S | (R)-Praziquantel-d11 |
(R)-Praziquantel-d11 is the deuterium labeled (R)-Praziquantel. (R)-Praziquantel, the active enantiomer of Praziquantel, is a partial agonist of the human 5-HT2B receptor. (R)-Praziquantel acts as an antischistosomal eutomer.
|
|
/
|
| HY-120692 | Cyclanoline chloride |
Cyclanoline chloride is an alkaloid. Cyclanoline chloride can be isolated from Fangji. Cyclanoline (chloride) inhibits the phosphorylation of JAK2 and STAT3, and induces Apoptosis. Cyclanoline chloride suppresses tumor growth in subcutaneous bladder cancer xenograft models of nude mice. Cyclanoline chloride reverses cisplatin resistance in bladder cancer cells and enhances the efficacy of Cisplatin (HY-17394). Cyclanoline chloride can be used for research related to bladder cancer.
|
|
/
|
| HY-17447AG | Tranylcypromine hydrochloride (GMP) |
Tranylcypromine (SKF 385) hydrochloride (GMP) is Tranylcypromine hydrochloride (HY-17447A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tranylcypromine hydrochloride is a potent monoamine oxidase (MAO) inhibitor.
|
|
/
|
| HY-N0565S1 | Doxycycline-d3 (hyclate) (major) |
Doxycycline-d3 hyclate (major) is the deuterium labeled Doxycycline hyclate (HY-N0565B). Doxycycline hyclate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hyclate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hyclate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hyclate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hyclate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hyclate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
|
/
|
| HY-154924 | Thio-NADP |
|
/
|
|
| HY-176785S | MCB-294 |
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
|
|
/
|
| HY-P2435 | Bz-Nle-Lys-Arg-Arg-AMC |
Bz-Nle-Lys-Arg-Arg-AMC can be used for protease activity assay. In 0.1mL Tris-HCl buffer (50 mM, pH 7.8), Bz-Nle-Lys-Arg-Arg-AMC was hydrolyzed, and the release rate of AMC was observed.
|
|
/
|
| HY-D0193A | Ponceau 4R (85%) |
Ponceau 4R (85%) (Acid Red 18 (85%); New Coccine (85%)) is an orally active synthetic food colorant and a HSA-binding aggregator. Ponceau 4R (85%) binds to HSA, inducing its partial unfolding, conformational changes and aggregation. Ponceau 4R (85%) serves as a food colorant and can be used in research on diseases including type Ⅱ diabetes, Parkinson's disease, Huntington's disease and spongiform encephalopathy.
|
|
/
|
| HY-P990902 | Atigotatug |
Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC50 of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a Kd of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models.
Species: Human |
|
/
|
| HY-N2732 | 6-Prenylapigenin |
6-Prenylapigenin (6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin) is a prenylated flavonoid that exists in the stems and leaves of Maclura pomifera. 6-Prenylapigenin exhibits cytotoxicity against cancer cells such as leukemia cells and solid tumor cells.
|
|
/
|
| HY-W110542O | Poly(ethylene glycol) diacrylate (MW 575),MEHQ as inhibitor |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 575), MEHQ as inhibitor is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 575), MEHQ as inhibitor can be used for the synthesis of a class of biodegradable polymers.
|
|
/
|
| HY-14546S | Aripiprazole-d8 |
Aripiprazole-d8 (OPC-14597-d8) is the deuterium labeled Aripiprazole (HY-14546). Aripiprazole (OPC-14597), an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole can be used for the research of schizophrenia and COVID19.
|
|
/
|
| HY-D2415 | BODIPY-FL staurosporine |
BODIPY-FL staurosporine (Compound 8a) is a fluorescence probe based on staurosporine, exhibiting high specificity towards tyrosine kinases (TK) and tyrosine kinase-like (TKL) family kinases. BODIPY-FL staurosporine has the potential to develop binding assays for kinases that are not recommended for use with Kinase Tracer 236, such as PIM3, CDC42BPG, MAP2K7, TXK, and SIK3. BODIPY-FL staurosporine can be a powerful tool for analyzing kinase selectivity in kinase drug discovery.
|
|
/
|
| HY-P3617 | Glucagon (22-29) |
Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca2+ pump in liver plasma membranes independently of adenylate cyclase activation.
|
|
/
|
| HY-141591 | CYT296 |
CYT296 is a target chromatin de-condensation compound. CYT296 can improve the induction of induced pluripotent stem cell (iPSCs) mediated by defined factors (OSKM) and induce an open chromatin state in Mouse Embryonic Fibroblast (MEFs) to facilitate somatic cell reprogramming. CYT296 can be used for cell replacement therapies and drug screening research.
|
|
/
|
| HY-P991319 | TAB-004 |
TAB-004 is a murine IgG1 monoclonal antibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.
Species: Human |
|
/
|
| HY-P99746 | Murlentamab |
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming.
Species: Human |
|
/
|
| HY-W110542D | Poly(ethylene glycol) diacrylate (MW 1000) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 1000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine.
|
|
/
|
| HY-78197 | 3,5-Dimethylisoxazole-4-boronic acid pinacol ester |
3,5-Dimethylisoxazole-4-boronic acid pinacol ester is a drug intermediate that can be used for the synthesis of bromodomain inhibitors.
|
|
/
|
| HY-DY1102 | BODIPY FL-C16 (solution) |
BODIPY FL-C16 (solution) is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 (solution) also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with Kd values of 270 nM and 330 nM, respectively. BODIPY FL-C16 (solution) is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles.
Solvent and concentration: DMSO: 5 mM |
|
/
|
| HY-13418G | Dorsomorphin dihydrochloride (GMP) |
Dorsomorphin dihydrochloride (GMP) is the GMP level of Dorsomorphin dihydrochloride (HY-13418). GMP guidelines are used to produce Dorsomorphin dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Dorsomorphin dihydrochloride (GMP) is a potent, selective and ATP-competitive AMPK inhibitor. Dorsomorphin dihydrochloride (GMP) can be used for the research of induced differentiation of pluripotent stem cells (PSCs).
|
|
/
|
| HY-W011338S | Benzyl butyl phthalate-d4 |
Benzyl butyl phthalate-d4 is the deuterium labeled Benzyl butyl phthalate. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs).
|
|
/
|
| HY-W008951 | Ethylenediaminetetra(methylenephosphonic acid) |
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers.
|
|
/
|
| HY-N0600 | Ginsenoside F3 |
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
|
|
/
|
| HY-N0175R | Cytisinicline (Standard) |
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs, and partial to full agonist at β4 containing receptors and α7 receptors. Has been used medically to help with smoking cessation.
|
|
/
|
| HY-174976 | FHND5032 |
FHND5032 is an orally active miR-124 inducer. FHND5032 significantly upregulates miR-124 expression in macrophages. FHND5032 disrupts inflammatory signaling, promotes macrophage reprogramming, and restores the epithelial barrier function by inhibiting the PIK3R2/PI3K/Akt axis. FHND5032 alleviates colitis and reduces inflammatory burden in ulcerative colitis mice. FHND5032 can be used for the study of ulcerative colitis.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Bacterial Infection
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
/
|
| HY-113293BS1 | Estrone sulfate-d4 sodium |
Estrone sulfate-d4 sodium is the deuterium labeled Estrone sulfate sodium (HY-113293B). Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research.
|
|
/
|
| HY-P11058 | OVA(250-264) |
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
|
|
/
|
| HY-P99169 | Uliledlimab |
|
/
|
|
| HY-N2103 | Tenacissoside G |
Tenacissoside G is a C21 steroid from the stems of Marsdenia tenacissima. Tenacissoside G reverses multidrug resistance in P-glycoprotein (Pgp)-overexpressing multidrug-resistant cancer cells.
|
|
/
|
| HY-D0917 | NIR-Red Dead Cell-1 Dye |
NIR-Red Dead Cell-1 Dye is a DNA-binding fluorescent dye for non-living cells (Ex/Em=515 nm/531 nm). NIR-Red Dead Cell-1 Dye can intercalate into base pairs of double-stranded DNA and produce stronger fluorescence. NIR-Red Dead Cell-1 Dye is suitable for necrotic cells or late apoptotic cells with damaged cell membranes, showing green fluorescence under fluorescence microscopy or flow cytometry. NIR-Red Dead Cell-1 Dye can be used to distinguish live cells from dead cells and distinguish cell membrane integrity. NIR-Red Dead Cell-1 Dye can be attached to the surface of Feraheme (FH) nanoparticles (NPs) to obtain fluorescent dye-functionalized NPs for drug delivery studies.
|
|
/
|
| HY-P990981 | Clesitamig |
Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC).
Species: Human |
|
/
|
| HY-W110542N | Poly(ethylene glycol) diacrylate (MW 250),MEHQ as inhibitor |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 250), MEHQ as inhibitor is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 250), MEHQ as inhibitor can be used to construct optical cross-linked hydrogel implants.
|
|
/
|
| HY-W110542J | Poly(ethylene glycol) diacrylate (MW 700) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 700) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 700) mimics the extracellular matrix (ECM), providing support and growth space for cells.
|
|
/
|
| HY-P5285 | Lunasin |
Lunasin is a bioactive peptide with antioxidant, anti-inflammatory, anticancer and anti-aging properties. Lunasin can be isolated from soybean. Lunasin also has an epigenetic mechanism of action associated with histone acetylation. Lunasin can be internalized into cells and inhibit Oncosphere formation in cancer cells.
|
|
/
|
| HY-Y1091 | D-Lysine |
D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
|
|
/
|
| HY-W110542P | Poly(ethylene glycol) diacrylate (MW 4000), MEHQ as inhibitor |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 4000), MEHQ as inhibitor is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 4000), MEHQ as inhibitor can be used to construct enzyme-responsive hydrogel drug delivery system.
|
|
/
|
| HY-167832 | PT109 |
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease.
|
JNK
SGK
ROCK
Tau Protein
MMP
DNA/RNA Synthesis
Pyruvate Kinase
NF-κB
COX
NO Synthase
Reactive Oxygen Species (ROS)
|
/
|
| HY-N0229R | L-Alanine (Standard) |
L-Alanine (Standard) is the analytical standard of L-Alanine. This product is intended for research and analytical applications. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
In Vitro: The viability of both hiPSCs, 201B7 cells and ehiPSCs decrease with an increase in L-Alanine concentration, and reach 7.5±1.3% and 3.7±0.7% respectively at 1.2 M of L-Alanine. On the other hand, no decrease in the viability of hFBs and hSkMCs are observed. Although the viability of iCMs slightly decreases along with the increase of the L-Alanine concentration, viability of iCMs at 1.2 M concentration of L-Alanine, 49.4±6.9%, is significantly higher than that of undifferentiated iPSCs, 201B7 cells and ehiPSCs (p< 0.01). The viability of hiPSCs, 201B7 cells and ehiPSCs, drastically decrease even after 2 or 4 h treatment. In contrast, the viability of hFBs fails to decrease at 1, 2, and 4 h and shows a small decrease at 24 h treatment. The viability of 201B7 cells in suspension culture decreases to 11.8±6.0% following treatment with 1.2 M L-Alanine for 2 h, whereas that of hFBs is 72.9±14.2%.
|
|
/
|
| HY-P5542 | Vicatertide |
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a Ka of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases.
|
|
/
|
| HY-Y0332K | Potassium dihydrogen phosphate, for cell culture |
Potassium dihydrogen phosphate, for cell culture (Potassium phosphate monobasic, for cell culture) is a cell culture reagent. Potassium dihydrogen phosphate, for cell culture activates NF-κB. Potassium dihydrogen phosphate, for cell culture upregulates the expression of dental/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) and enhances the mineralization capacity of human periodontal ligament stem cells. Potassium dihydrogen phosphate, for cell culture promotes the proliferation of human periodontal ligament stem cells in logarithmic growth phase. Potassium dihydrogen phosphate, for cell culture promotes the growth of somatic embryos of Dendrobium Sonia, increases leaf number, leaf length and fresh weight of tissue-cultured seedlings. Potassium dihydrogen phosphate, for cell culture is applicable to periodontal disease-related research.
|
|
/
|
| HY-P991155 | Ramantamig |
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma.
Species: Human |
|
/
|
| HY-P990650 | PY159 |
PY159 is a humanized antibody targeting TREM1/CD354. PY159 reprograms immunosuppressive intratumoral myeloid cells towards an inflammatory, anti-tumor phenotype, promotes anti-tumor immune responses, upregulates monocyte activation markers, and induces proinflammatory cytokines. PY159 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, and advanced refractory solid tumors.
Species: Human |
|
/
|
| HY-W015466 | Acetylvaline |
Acetylvaline is a class of amino acid derivative metabolites. The expression abundance of Acetylvaline is upregulated under heat stress conditions; it participates in the regulation of amino acid biosynthesis, cysteine and methionine metabolic pathways, and mediates the physiological processes of antioxidant defense and energy metabolism reprogramming in Magallana sikamea. Acetylvaline can be released from acetylvalyl-RNA of Turnip Yellow Mosaic Virus (TYMV) by N‑acylaminoacyl‑tRNA hydrolase. Acetylvaline can be used in metabolism-related research.
|
|
/
|
| HY-D0053 | 6-ROX |
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2.
|
|
/
|
| HY-N0729D | Linoleic acid,suitable for cell culture |
Linoleic acid is a critical component of polyunsaturated fatty acids. Linoleic acid reduces GSH-PX and T-SOD activities. Linoleic acid functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid can cause acute oxidative damage to red blood cells, ultimately leading to partial acute anemia. Linoleic acid can be used in the research of skin diseases associated with linoleic acid deficiency.
|
|
/
|
| HY-124081 | N-Oleoyl-L-serine |
N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development.
|
|
/
|
| HY-P99286 | Drozitumab |
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma.
Species: Human |
Leukemia/Lymphoma/Myeloma
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Metastatic Colorectal Cancer
|
/
|
| HY-131131 | 5-CFDA-AM |
5-CFDA-AM is a cell-permeable esterase substrate that can be used as an active probe to measure enzyme activity and cell membrane integrity. 5-CFDA-AM is electroneutral and can enter the cell at a lower concentration than CFDA, where it is hydrolysed by intracellular esterases to produce carboxyfluorescein, which contains an additional negative charge and can be better retained in the cell. 5-CFDA-AM can be used to detect cell viability.
|
|
/
|
| HY-N2122 | Neoisoliquiritin |
Neoisoliquiritin (Neoisoliquiritigenin) is an androgen receptor (AR) inhibitor. Neoisoliquiritin inhibits the ATPase activity of GRP78. Neoisoliquiritin induces G0/G1 cell cycle arrest and inhibits proliferation in cancer cells, while it also induces cell apoptosis (apoptosis). Neoisoliquiritin suppresses tumor growth in mouse models of prostate cancer and breast cancer. Neoisoliquiritin can be used in studies related to prostate cancer and breast cancer.
|
|
/
|
| HY-Y1365L | Porcine skin Gelatin,suitable for cell culture(high gel strength) |
Porcine skin Gelatin,suitable for cell culture(high gel strength) can be used to coat cells to improve cell attachment.
|
|
/
|
| HY-P99794 | Osocimab |
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
Species: Human |
|
/
|
| HY-N0140R | Ursolic acid (Standard) |
Ursolic acid (Standard) is the analytical standard of Ursolic acid. This product is intended for research and analytical applications. Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
|
|
/
|
| HY-P990059 | Puxitatug |
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.
Species: Human |
|
/
|
| HY-Y0317H | Sodium sulfate anhydrous, for cell culture |
Sodium sulfate anhydrous, for cell culture is a drying agent in organic synthesis, which can be used for cell culture.
|
|
/
|
| HY-P10810 | QPH-FR |
QPH-FR is a LGR5 inhibitor. QPH-FR competitively binds to LGR5 and prevents the formation of the LGR5/RSPO1 complex. QPH-FR promotes RNF43/ZNRF3-mediated ubiquitination of FZD receptors, inhibits the Wnt β-catenin signaling pathway, and reduces the stemness of colorectal cancer cells. QPH-FR is applicable to relevant research on colorectal cancer.
|
|
/
|
| HY-W259767 | 3-Iodo-L-phenylalanine |
3-Iodo-L-phenylalanine is an unnatural amino acid that can be used for partial codon redistribution. 3-Iodo-L-phenylalanine has a high efficiency in Ser AGU codon reassignment, and also has a certain effect in Ser UCG codon reassignment. 3-Iodo-L-phenylalanine can be used in the study of genetic code expansion and protein engineering.
|
|
/
|
| HY-W094475C | Magnesium sulfate heptahydrate, for cell culture |
Magnesium sulfate heptahydrate, for cell culture (Epsom salts, for cell culture) is a hydrate of magnesium sulfate (HY-Y1267) suitable for cell culture applications. Magnesium sulfate is a calcium antagonist and a potent L-type calcium channel inhibitor, as well as a tocolytic. Magnesium sulfate has anti-inflammatory, anticonvulsant, vasodilatory, and neuroprotective effects. Magnesium sulfate can be used in the research of diseases such as preeclampsia/eclampsia.
|
|
/
|
| HY-Y1365D | Bovine Gelatin,suitable for cell culture |
Bovine Gelatin, suitable for cell culture can be used for cell culture to induce cell attachment.
|
|
/
|
| HY-137042 | Cyanine5 alkyne |
Cyanine5 alkyne (Alkyne-Cy5) is a fluorescent dye used to label azide proteins and can be used to analyse post-translational modifications of proteins, glycosylation etc. Cyanine5 alkyne can also be used as a mitochondrial OXPHOS inhibitor to inhibit the growth of cancer stem cells (CSC). Cyanine5 alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
|
/
|
| HY-W015236 | H-Gly-Gly-Gly-OH |
H-Gly-Gly-Gly-OH, also known as Triglycine, is a tripeptide composed of glycine, glycine and glycine, which are linked by peptide bonds. Often used as a model compound in the study of protein structure and function. Glycylglycylglycine also acts as a neurotransmitter in the central nervous system and has been shown to have antioxidant properties. Furthermore, it may have potential research roles in various diseases such as cancer, diabetes and neurodegenerative diseases.
|
|
/
|
| HY-W110542G | Poly(ethylene glycol) diacrylate (MW 6000) |
Poly(ethylene glycol) diacrylate (PEGDA) (MW 6000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 6000) can be used as a building material for wound dressing hydrogels.
|
|
/
|
| HY-D1736 | BODIPY FL-C16 |
BODIPY FL-C16 is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with Kd values of 270 nM and 330 nM, respectively. BODIPY FL-C16 is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles.
|
|
/
|
| HY-156002 | LUNA18 |
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer.
|
|
/
|
| HY-W087830 | L-p-Boronophenylalanine |
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma.
|
|
/
|
| HY-P990673 | Vandortuzumab |
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC).
Species: Human |
|
/
|
| HY-Y1365 | Gelatins |
Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy.
|
|
/
|
| HY-P7083 | IL-9 Protein, Mouse (CHO, His) |
|
/
|
|
| HY-P78763 | Coagulation factor VII/F7 Protein, Human (HEK293, His) |
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor VII/F7, expressed by HEK293, with C-His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P70763 | IgG1 Protein, Mouse (HEK293) |
The immunoglobulin heavy chain constant region is the heavy chain constant region of immunoglobulin. Sequence differences between immunoglobulin heavy chains leads to the various isotypes with different characteristic. IgG1 Protein, Mouse (HEK293) is the recombinant mouse-derived IgG1 protein, expressed by HEK293 , with tag free.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P74239 | Coagulation Factor VII/F7 Protein, Human (HEK293, His, solution) |
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation Factor VII/F7 Protein, Human (HEK293, His, solution) is the recombinant human-derived Coagulation Factor VII/F7 protein, expressed by HEK293 , with C-His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P71823 | KIR2DS1 Protein, Human (P.pastoris, His) |
KIR2DS1, on NK cells, acts as a receptor for specific HLA-C alleles, like w6, without inhibiting NK cell activity. Interacting with the adapter protein TYROBP/DAP12, their collaboration enhances KIR2DS1 stability at the cell surface. This dynamic interplay highlights the intricate regulatory mechanisms associated with KIR2DS1, contributing to the modulation of NK cell responses. KIR2DS1 Protein, Human (P.pastoris, His) is the recombinant human-derived KIR2DS1 protein, expressed by P. pastoris , with N-6*His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P72274 | Islet cell autoantigen 1/ICA1, Human (P.pastoris, His) |
ICA1 may be involved in neurotransmitter secretion, suggesting involvement in synaptic transmission. It may help regulate the release of neurotransmitters, a key aspect of neuronal communication. Islet cell autoantigen 1/ICA1, Human (P.pastoris, His) is the recombinant human-derived Islet cell autoantigen 1/ICA1, expressed by P. pastoris , with N-6*His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P705930 | ITK Protein, Human (Active, 269a.a, sf9, His, GST) |
ITK protein is an important tyrosine kinase that regulates adaptive immune responses by affecting the development and function of T cells and NKT cells. Upon T cell receptor (TCR) activation, ITK undergoes LCK-mediated phosphorylation, leading to its activation. ITK Protein, Human (Active, 269a.a, sf9, His, GST) is the recombinant human-derived ITK, expressed by Sf9 insect cells, with His and GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P74795 | ITK Protein, Mouse (sf9, His-GST) |
ITK protein is a tyrosine kinase that plays a crucial role in directing adaptive immune responses by controlling the development, function, and differentiation of conventional T cells and unconventional NKT cells.After T cell receptor (TCR) activation by antigen-presenting cells (APC), ITK is recruited to the cell membrane and phosphorylated by LCK, thereby making it fully activated.ITK Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived ITK protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
Species: Mouse; Source: Sf9 insect cells |
|
/
|
| HY-P73045 | Coagulation Factor VII/F7 Protein, Mouse (CHO, His) |
Coagulation Factor VII (F7) protein lacks crucial conserved residue(s) needed for propagating feature annotation. Coagulation Factor VII/F7 Protein, Mouse (CHO, His) is the recombinant mouse-derived Coagulation Factor VII/F7 protein, expressed by CHO , with C-His labeled tag.
Species: Mouse; Source: CHO |
|
/
|
| HY-P700565 | Coagulation factor VII/F7 Protein, Human (His-SUMO) |
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (His-SUMO) is the recombinant human-derived Coagulation factor VII/F7 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P87311 | CXCL13 Antibody (YA6994) |
CXCL13 Antibody (YA6994) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CXCL13.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P810499 | QSOX1 Antibody (YA9792) |
QSOX1 Antibody (YA9792) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to QSOX1.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P81660 | CD7 Antibody (YA1405) |
|
/
|
|
| HY-P81660A | CD7 Antibody (YA1405)(PBS only) |
|
/
|
|
| HY-P85013 | CD96 Antibody (YA4705) |
|
/
|
|
| HY-P85897 | CD7 Antibody (YA5589) |
|
/
|
|
| HY-P85998 | Mast cell tryptase Antibody (YA5690) |
Mast cell tryptase Antibody (YA5690) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mast cell tryptase.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P86015 | Mast cell tryptase Antibody (YA5707) |
Mast cell tryptase Antibody (YA5707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mast cell tryptase.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P88693 | FATE1 Antibody (YA8377) |
FATE1 Antibody (YA8377) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FATE1.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P88693A | FATE1 Antibody (YA8377)(PBS only) |
FATE1 Antibody (YA8377) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FATE1.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P811174 | Factor VII Antibody |
Factor VII Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Factor VII.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-K0308 | Mouse CD4+ Cell Positive Selection Kit |
MCE Mouse CD4+ Cells Positive Selection Kit is designed for the isolation of CD4+ cells from single cell suspensions of mouse spleen cells, lymph nodes or other tissues. |
|
/
|
| HY-K0309 | Mouse CD8+ T Cells Negative Selection Kit |
MCE Mouse CD8+ T Cells Negative Selection Kit is designed for the isolation of CD8+ T cells from single cell suspensions of mouse spleen cells and lymph nodes. |
|
/
|
| HY-K0354 | Mouse CD3/CD28 T Cell Activation Magnetic Beads |
MCE Mouse CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation. |
|
/
|
| HY-K0357 | Mouse Mature B Cell Negative Selection Kit |
MCE Mouse Mature B Cell Negative Selection Kit enables the efficient isolation of mature B cells from single-cell suspensions prepared from mouse spleen, lymph nodes, or bone marrow. The principle involves using biotin-labeled monoclonal antibodies to label non-target cells (non-B cells), followed by the removal of these non-target cells through streptavidin-labeled magnetic beads, achieving the selective isolation of mouse mature B cells. |
|
/
|
| HY-K2034 | OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells) |
MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies. |
|
/
|
| HY-K3022 | Recombinant Human Serum Albumin Solution (rHSA, 20%) |
MCE Recombinant Human Serum Albumin Solution (rHSA, 20%) can be widely used in various cell culture systems and is particularly suitable for maintaining the undifferentiated growth and expansion of human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) under both feeder-dependent and feeder-free conditions. |
|
/
|
| HY-K3037 | McCoy’s 5A (Modified) Medium |
MCE McCoy's 5A Modified Medium is a nutrient-rich medium designed for culturing a wide range of cell types, particularly suitable for supporting the growth of primary cells. It is widely used for the culture of various mammalian cells, including normal and tumor-derived cells, epithelial cells, fibroblasts, bone marrow cells, and other cell types. The product specifications are based on the 500 mL format, and larger volume packages are provided as multiples of this standard specification. |
|
/
|
| HY-K6006 | Basement Membrane Matrix IPSC-qualified |
MCE Basement Membrane Matrix IPSC-qualified is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for stem cells culture. |
|
/
|
| HY-K6020 | iPSC/ESC Dissociation Solution (Enzyme-Free) |
MCE iPSC/ESC Dissociation Solution (Enzyme-Free) is a chelation-based, enzyme-free cell dissociation reagent specifically designed for the culture and manipulation of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). This optimized solution enables gentle and efficient dissociation of iPSCs/ESCs within 5-8 min, making it suitable for routine passaging, dissociation, and cell-cluster handling. It provides superior stability and better preservation of cell state compared with traditional methods. |
|
/
|
| HY-K6024 | Stem Cell Basement Membrane Matrix (Ready-to-Use) |
MCE Stem Cell Basement Membrane Matrix (Ready-to-Use) is pre-diluted using an optimized formulation and requires no additional dilution or preparation. It is designed for direct use in stem cell culture applications, including cell attachment, expansion, and pluripotency maintenance, and is suitable for the culture and differentiation of hESCs, iPSCs, and other pluripotent stem cells. |
|
/
|
| HY-K6101A | Human Breast Cancer Organoid Complete Culture Medium |
MCE Human Breast Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal breast cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human breast cancer organoid models. |
|
/
|
| HY-K6104A | Human Colorectal Cancer Organoid Complete Culture Medium |
MCE Human Colorectal Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal colorectal cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human colorectal cancer organoid models. |
|
/
|
| HY-K6105A | Human Gastric Cancer Organoid Complete Culture Medium |
MCE Human Gastric Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal gastric cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human gastric cancer organoid models. |
|
/
|
| HY-K6123A | Human Ovarian Cancer Organoid Complete Culture Medium |
MCE Human Ovarian Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal ovarian cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human ovarian cancer organoid models. |
|
/
|
| HY-K6301 | Human iPSC/ESC Cortical Brain Organoid Induction Differentiation Kit |
MCE Human iPSC/ESC Cortical Brain Organoid Induction Differentiation Kit is a standardized culture system specifically designed to recapitulate the developmental processes and functional features of the human cerebral cortex through forebrain ventralization-based signaling regulation. By sequentially activating the Wnt/β-catenin pathway and gradually inhibiting BMP/Smad signaling, this system efficiently drives human pluripotent stem cells (PSC) to differentiate into high-purity glutamatergic neurons (VGLUT1/2+ > 85%), while simultaneously promoting the formation of Pax6+/BLBP+ radial glial cells that establish a biomimetic ventricular-zone–like structure. |
|
/
|
| HY-K6302 | Human iPSC/ESC Whole-Brain Organoid Induction Differentiation Kit |
MCE Human iPSC/ESC Whole-Brain Organoid Induction Differentiation Kit is a non-region-specific brain organoid induction kit designed based on the neuroectoderm self-differentiation system. After 38 d of culture using this kit, the resulting whole-brain organoids stably express core neuronal markers such as TUJ1, SOX2, Nestin, and NeuN, as well as forebrain/cortical markers including FOXG1 and CTIP2. |
|
/
|
| HY-K6303 | Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit |
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies. |
|
/
|
| HY-K6304 | Human iPSC/ESC Hepatocyte Induction Differentiation Kit |
MCE Human iPSC/ESC Hepatocyte Induction Differentiation Kit enables the efficient generation of hepatocyte-like cells with a high degree of maturation within 21 d. The resulting cells stably express multiple key hepatic functional markers, including albumin (ALB), cytochrome P450 (CYP) family enzymes, and other liver-specific functional molecules, and exhibit typical hepatocellular phenotypes and functions. |
|
/
|
| HY-K6501 | Human PSC Maintenance Medium |
MCE Human PSC Maintenance Medium is a ready-to-use, chemically defined formulation designed to support the robust growth and self-renewal of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) under feeder-free culture conditions. |
|
/
|
| HY-K6502 | Human iPSC-Derived Brain Organoid Long-term Culture Medium |
MCE Human iPSC-Derived Brain Organoid Long-term Culture Medium is a specialized culture system developed through systematic reformulation and concentration optimization based on neuronal cell culture platforms. It significantly enhances the adaptability and stability of long-term culture for brain organoids derived from human induced pluripotent stem cells (iPSCs). |
|
/
|
| HY-K6504 | Human iPSC/ESC Cortical Brain Organoid Maturation Medium |
MCE Human iPSC/ESC Cortical Brain Organoid Maturation Medium is a ready-to-use culture system specifically formulated for the long-term maintenance and maturation of cortical brain organoids. It serves as a seamless transition from the induction phase and supports the continued growth and functional development of the organoids. Upon switching PSC-derived cortical brain organoids to this medium, organoid viability and structural stability are markedly enhanced, enabling a robust and extended culture period of up to 180 d. |
|
/
|
Targets/Pathways
































































































































































